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Abstract 
Background and objectives 
In recent years, the European collaboration in health technology assessments 
(HTAs), not only on pharma products but also on (high-risk) medical devic-
es and procedures has become a major issue of consideration due to weak 
market authorization and efficacy/safety concerns. This research sought to ex-
plore and synthesize the critical points and challenges in the assessment of 
medical devices in Europe discussed in publications and to analyze a num-
ber a selected European HTA reports regarding their timing in relation to 
market authorization (CE-mark), levels of evidence considered in the assess-
ments and overlaps in topics.  
Methods 
A literature review of publications searched in Medline via PubMed supple-
mented by a grey literature search was conducted to identify the critical 
points and challenges in the assessment of medical devices in Europe. Then 
the ADVANCE HTA database (developed in the EU-FP7 project) was used 
to select a cohort group of HTA reports on high-risk medical devices conduct-
ed in 2014: Ten devices and their respective reports were selected for further 
investigation. Finally, a search in several databases was conducted to find 
additional HTA reports on the selected technologies in earlier or later years.  
Results 
The issues discussed in the recent literature can be summarized in five ma-
jor critical points in the assessment of medical devices: 1. Missing of robust 
evidence at time of assessment; 2. Methodologic challenges; 3. Need for har-
monization of HTA-requirements; 4. Variable impact on decisions; 5. Tim-
ing of HTA in life-cycle of medical devices. 
The analyses of HTA reports on 10 selected high-risk medical devices t re-
vealed the amount of the redundancies in European HTA production: the 
number of reports per technology ranged between 5 and 22 reports over a 
time-span of 10-12 years; ranging between 1-6 reports of the same technology 
within the same year, sometimes even within the same country (language).  
Discussion and conclusion 
The results strongly support the assumption that the resources of HTA insti-
tutes can be used more efficiently. In contrast to pharma products entering 
the health care systems at almost the same time, medical devices and accord-
ingly their pre-reimbursement assessments show a broader time-span (up to 
12 years) in Europe. The knowledge gained contributes to the conclusion that 
there is a need not only to collaborate across borders within the same year 
but also to build on each other´s assessments of the same technologies over 
years by using the same format, method, language.  
 
HTA on high-risk 
medical devices:  
 
research questions: 
critical points discussed 
timing + evidence used 
in HTAs  
literature review  
 
HTA reports analyses  
of 10 selected medical 
devices 
5 major critical points 
are discussed in 
literature  
high redundancy of HTA 
of medical devices:  
up to 22 reports of same 
tech over time-span of 
12 years 
collaboration: 
not only within the 
same HTA at 1 point in 
time, but building on 
each other by using: 
same language 
same method 
same format 
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1 Introduction 
All over the world healthcare systems struggle with the increasing pressure 
of using their given resources in the most efficient way.1 The healthcare sys-
tems are not able to satisfy the health related demands of the population, par-
ticularly in the light of progressive aging and awareness of new and emerging 
health technologies.2 New health technologies are often seen as a key driver 
for the increased health expenditures.  
Health Technology Assessment (HTA) is one approach that has been widely 
adopted to support the introduction and appropriate use of new and emerging 
health technologies and procedures.3 Health technology itself is a very broad 
term and refers to medical devices, procedures, pharmaceuticals and the re-
sponsible organizational and support systems which provide health care.4 
HTA aims to provide coverage bodies and policy makers with information 
regarding the clinical and economic value of the new technologies.5, 6 Hence, 
HTA can be considered as a „bridge between the world of research and the 
world of decision-making, particularly policy-making”7.  
This study focuses on HTA for medical devices. In recent years, medical de-
vices have become more and more instrumental in health care. It has been 
acknowledged that patients nowadays enjoy longer lives of higher quality 
thanks to the contribution of medical device technologies.8 Especially with 
regard to surgeries, medical devices made new innovative methods feasible 
by the use of imaging tools, implants or innovative instruments.9  
The definition by the European Union (EU) Directive 2007/47/EC (amend-
ment of the Council Directive 93/42/EEC on medical devices) describes med-
ical devices as „any instrument, apparatus, appliance, software, material or 
other article, whether used alone or in combination, together with any acces-
sories, including the software intended by its manufacturer to be used specif-
ically for diagnostic and/or therapeutic purposes and necessary for its prop-
er application, intended by the manufacturer to be used for human beings 
for the purpose of: 
 
 
                                                             
1 Iglesias, “Does Assessing the Value for Money of Therapeutic Medical Devices 
Require a Flexible Approach?” 
2 Battista and Hodge, “The Evolving Paradigm of Health Technology Assessment.” 
3 Banta, “The Development of Health Technology Assessment.” 
4 International Journal of Technology Assessment in Health Care, “Health Technology 
Assessment.” 
5 International Journal of Technology Assessment in Health Care, “Health Technology 
Assessment.” 
6 Iglesias, “Does Assessing the Value for Money of Therapeutic Medical Devices 
Require a Flexible Approach?” 
7 Battista and Hodge, “The Evolving Paradigm of Health Technology Assessment.” 
8 Kramer, Xu, and Kesselheim, “How Does Medical Device Regulation Perform in 
the United States and the European Union?” 
9 Sauerland et al., “Approaches to Assessing the Benefits and Harms of Medical 
Devices for Application in Surgery.” 
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 diagnosis, prevention, monitoring, treatment or alleviation of disease,  
 diagnosis, monitoring, treatment, alleviation of or compensation for 
any injury or handicap,  
 investigation, replacement or modification of the anatomy or of 
a physiological process,  
 control of conception  
and which does not achieve its principal intended action in or on the human 
body by pharmacological, immunological or metabolic means, but which may 
be assisted in its function by such means”10. Therefore, medical devices are 
regarded as a very broad and heterogeneous group of products, which ranges 
from bandages and stethoscopes to active implantable pacemakers and hip 
prostheses.11 Additionally, medical devices differ in form of their use from 
patients to medical professionals and their application for therapeutic or di-
agnostic purposes.12 The regulatory framework, as well as the definition of 
medical devices and classification of risk classes, varies from country to coun-
try and sometimes even within economic regions.13 
The market of medical devices, including diagnostic products, is one of the 
fastest growing in healthcare. Compared to pharmaceuticals, medical devices 
have nearly twice as many patent applications (over 10.000) filed in Europe 
in 2012.14 Furthermore, experts estimate that about 150 new high-risk medi-
cal devices enter the market every year.15 The total number of medical and 
in vitro diagnostic devices on the market in Europe is over 500.000.16 25.000 
enterprises, most of them being small and medium-sized (SMEs) produce 
medical devices in Europe, generating nearly 100 billion Euro annual sales 
in the European market.17  
In consideration of the increasing health care expenditures of European health 
care systems, the scarce human and financial resources, and the influence of 
the medical device industry in Europe, this research looks into the challeng-
es of conducting HTAs on medical devices to support efforts towards inten-
sified collaboration between HTA institutes on a European level.  
 
 
                                                             
10 “The European Parliament and the Council of the European Union.  
Directive 2007/46/EC of the European European Parliament and of the Council  
of 5 September 2007.” 
11 Schnell-Inderst et al., “Health Technology Assessment of Medical Devices.” 
12 Taylor and Iglesias, “Assessing the Clinical and Cost-Effectiveness of Medical 
Devices and Drugs.” 
13 Santos and Tavares, “Additional Peculiarities of Medical Devices That Should Be 
Considered in Their Development Process.” 
14 Craig et al., “A Review of the Economic Tools for Assessing New Medical Devices.” 
15 Sauerland et al., “Approaches to Assessing the Benefits and Harms of Medical 
Devices for Application in Surgery.” 
16 World Health Organization, “World Health Organization – Medical Devices.” 
17 European Council. Council of the European Union, “European Council. Council 
of the European Union – Modernising EU Rules for Medical Devices – Consilium.” 
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1.1 Aim and objective of the report  
This report aims to provide an overview of the challenges discussed in the 
recent literature on the assessment of medical devices in Europe. Further-
more, this research analyses the timing of the assessments and the level of 
evidence used by different HTA institutes. This may improve the collabora-
tion on a European level and help to use resources more efficiently.  
This research has two main objectives:  
 Firstly, to explore and explain the medical devices landscape from 
regulation to coverage and the resulting critical points and challenges 
in the assessment of medical devices.  
 Secondly, to analyze the timing and level of evidence of HTA reports 
by evaluating ten different high-risk technologies assessed by differ-
ent HTA institutes.  
 
 
2 aims: 
 
overview of challenges 
of HTA of medical 
devices discussed in 
literature  
comparison of HTAs of 
10 medical devices: 
timing, evidence 
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2 Theoretical Background  
This chapter provides an overview of the regulation of medical devices con-
sidering the pre-market evaluation as well as the assessment of medical de-
vices, an approach given by the EUnetHTA, the unique characteristics of 
medical devices as well as the differentiation to pharmaceuticals, and finally 
the results of the new EU directive for medical device regulation in Europe.  
 
 
2.1 Pre-Market Approval of Medical Devices  
The European Union published three directives for the classification of med-
ical devices to achieve a consistent regulatory framework through Europe: 
Council Directive 93/42/EEC on medical devices (MDD), Council Directive 
90/385/EEC on active implantable medical devices (AIMDD) and Council 
Directive 98/79/EC on in vitro diagnostic medical devices (IVDD).18 These 
three directives came into effect in the 1990s and regulate safety and market-
ing of medical devices in Europe and were incorporated into the national laws 
at the Member State level, which harmonizes the requirements needed.19, 20 
On June 15th, 2016 the Councils Committee confirmed the agreement with the 
European Parliament on a new medical device regulation for medical devices 
and in vitro medical devices. The aim of these new guidelines is to modernize 
the current legislations, including safety measures and allowing patient access 
to new innovations in a timely manner. In order to ensure safety of medical 
devices, regulations to get marketing approval are strengthened and combined 
with post-marketing surveillance.21 The special focus of this new regulation 
lies on: 
 Pre-market conformity assessment and the associated requirements, 
 Post-market control and supervision, 
 The possibility to trace medical devices and in vitro medical devices 
throughout the lifecycle.22  
                                                             
18 “European Parliament and Council of the European Union. Council Directive 90/ 
385/EEC of 20 June 1990 on the Approximation of the Laws of Member States Re-
lating to Active Implantable Medical Devices.”; “European Parliament and Coun-
cil of the European Union. Council Directive 93/42/EEC of 14 June 1993 Concern-
ing Medical Devices.”; “European Parliament and Council of the European Union. 
Council Directive 98/79/EC of 27 October 1998 on in Vitro Diagnostic Medical 
Devices.” 
19 French-Mowat and Burnett, “How Are Medical Devices Regulated in the 
European Union?” 
20 Tarricone et al., “Generating Appropriate Clinical Data for Value Assessment of 
Medical Devices.” 
21 European Council. Council of the European Union, “European Council. Council  
of the European Union – Medical Devices: Council Confirms Deal with EP – 
Consilium.” 
22 European Council. Council of the European Union, “European Council. Council of 
the European Union – Modernising EU Rules for Medical Devices – Consilium.” 
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The draft regulations change in detail: 
 Risk Levels  
The in vitro medical devices were classified in four risk categories, to 
be in line with the categorization of the medical devices classified in 
the Medical Device Directive (MDD).  
The risk level is determined by:  
 „The obligations placed on manufacturers and other economic 
operators  
 The requirements for clinical investigations and clinical evidence  
 The requirements for market surveillance by national authorities“23  
 Product conformity  
The manufacturer of the medical device has to appoint a qualified per-
son, who is in charge of ensuring that all requirements were success-
fully applied.  
 Traceability  
Manufacturers and importers are required to equip their devices with 
a Unique Device Identification (UDI). Further, manufacturers, import-
ers and products have to be registered in the European Union in a cen-
tral database. This shall help to track the devices from supply chain 
to the end-user. In addition, manufacturers are also required to report 
serious incidents and corrective actions on an EU portal.  
 Notified Bodies 
Notified Bodies (NB) are allowed to carry out unannounced factory 
inspections and to conduct physical or laboratory tests on the devices. 
The designation through the Member States still persists. However, the 
attendant decision would be subject to a joint assessment on which ex-
perts from the designating country, other countries, and the European 
Commission work and decide together.  
 Medical Device Coordination Group  
A medical device coordination group consisting of national represent-
atives will be installed to have a second look at the assessments of the 
Notified Bodies on high-risk medical devices before they receive the 
CE-mark and enter the European market.24 
Before a medical device can be put on the market in Europe, it has to receive 
the CE-mark (Conformité Européenne), which allows it to circulate freely 
throughout the European market.25 Moreover, the CE-mark can be seen as a 
declaration by the manufacturer that the medical device meets all require-
ments of the relevant legislation.26 The aim is to illustrate safety and perfor-
mance, however, a proof of efficacy is not relevant.27 
                                                             
23 Ibid. 
24 Ibid. 
25 Tarricone et al., “Generating Appropriate Clinical Data for Value Assessment of 
Medical Devices.” 
26 French-Mowat and Burnett, “How Are Medical Devices Regulated in the 
European Union?” 
27 voor de Gezondheidszorg, “The Pre-Market Clinical Evaluation of Innovative 
High-Risk Medical Devices.” 
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While broad and consistent legislation for the regulation of medical devices 
exists, the implementation remains the responsibility of the Member States.28 
Each Member State government nominates a Competent Authority (CA), to 
monitor and ensure compliance with the requirements given by the MDD.29 
These Competent Authorities accredit the so-called Notified Bodies (NB), 
which are commonly for-profit organizations. NBs are responsible for per-
forming the conformity assessment of medical devices.30 
The assessed medical device has to be classified by one of the four risk clas-
ses (1, 2a, 2b, 3). The classification depends on the characteristics of the de-
vice, such as duration of use and contact, active versus non-active devices and 
invasiveness or non-invasiveness of the device.31 For most devices of low risk 
(class 1, e.g. bandages, plasters) the manufacturer is allowed to assign the CE-
mark without the involvement of a NB, a so-called self-certification, and reg-
ister this product with a national Competent Authority.32 The other risk clas-
ses have to be reviewed by one of the Notified Bodies and include an assess-
ment of the device’s design and manufacturing quality system of the manu-
facturer as well as a review of clinical investigation studies.33 The manufac-
turer is free to choose which Notified Body in Europe is responsible for the 
evaluation and issuing a certificate of conformity.34 
A classic regulatory framework consists of the following parts: 
 Regulatory guidelines,  
 Governmental approved regulatory authority, 
 Conformity assessment bodies, 
 Classification scheme concerning potential risk to the user, 
 Quality management system, 
 System for evaluating the clinical safety and performance  
of the device, 
 System to allow market entrance, 
 Surveillance system for the device in the market.35  
Table 2.1-1 gives an overview about the pre-market evaluation in Europe, the 
risk classes as well as the general and essential requirements. 
                                                             
28 Campillo-Artero, “A Full-Fledged Overhaul Is Needed for a Risk and Value-Based 
Regulation of Medical Devices in Europe.” 
29 French-Mowat and Burnett, “How Are Medical Devices Regulated in the 
European Union?” 
30 Hulstaert et al., “Pre-Market Clinical Evaluations of Innovative High-Risk 
Medical Devices in Europe.” 
31 “European Parliament and Council of the European Union. Council Directive 
93/42/EEC of 14 June 1993 Concerning Medical Devices.” 
32 Ibid. 
33 Parvizi and Woods, “Regulation of Medicines and Medical Devices.” 
34 Campillo-Artero, “A Full-Fledged Overhaul Is Needed for a Risk and Value-Based 
Regulation of Medical Devices in Europe.” 
35 Santos et al., “Medical Device Specificities.” 
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Table 2.1-1: Summary of the authorization system in Europe (adapted from36) 
Regulatory body Decentralized system – Notified Bodies across Europe 
Classification  Risk class approach – Class 1, Class 2a, Class 2b and Class 3 
Procedure  Class 1 Class 2a Class 2b  Class 3 
General 
requirements  
General requirements  General requirements  General requirements  
Self-certification Essential requirements  Essential requirements  Essential requirements  
 Conformity assessment 
by NB 
Conformity assessment 
by NB 
Conformity assessment 
by NB 
Evidence 
requirements  
General requirements  Essential requirements  
 Safety 
 Performance 
 Risk-ratio  
 Safety  
 Performance  
 Risk-ratio  
 Packaging  
 Information on side effects 
 Chemical, physical and biological properties 
 Infection and microbial contamination  
 Construction and environmental properties 
 Information about measuring function 
 Information about protection against radiation  
 Labeling and information leaflet  
 
  
                                                             
36 Krüger and Wild, “Evidence Requirements for the Authorization and 
Reimbursement of High-Risk Medical Devices in the USA, Europe, Australia  
and Canada.” 
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2.2 Health Technology Assessment 
for Medical Devices 
Health Technology Assessment (HTA) is a broadly used and accepted way 
to support healthcare decisions and to manage the appropriate use of new 
and emerging health technologies in most of the healthcare systems in the 
world.37, 38 The expansion of HTA reflects the concerns over the unsustaina-
ble growth of health care systems. HTA can potentially mediate between pol-
icy and research domains by giving a „problem-oriented systematic overview 
of research”.39  
As a form of policy research, HTA has to examine short- and long-term conse-
quences of health technologies in a systematic way and support policy-makers 
in making evidence-based decisions.40, 41 Additionally, by using HTA, cover-
age bodies ensure that their decisions on coverage and reimbursement of new 
technologies are based on the best evidence available, considering the medi-
cal, social, ethical and economic implications of the health technology.42, 43 
The term health technology can be applied very broadly and includes medi-
cal devices, procedures, and pharmaceuticals, as well as the organizational sys-
tems that administer health care.44 Started 1987 in Sweden, today’s number 
of HTA institutes has grown up to over 90 institutes in Europe.45  
The European network for Health Technology Assessment (EUnetHTA), 
which is a network of governmental organizations and other contributors to 
HTA in Europe, defines HTA as a „multidisciplinary process that summa-
rizes information about the medical, social, economic and ethical issues re-
lated to the use of health technology in a systematic, transparent, unbiased, 
robust manner. Its aim is to inform the formulation of safe, effective, health 
policies that are patient focused and seek to achieve the best value”.46 The in-
tention of EUnetHTA is to collaborate in joint assessments and therefore to 
avoid duplication in the production of HTAs. 
                                                             
37 Drummond et al., “Key Principles for the Improved Conduct of Health 
Technology Assessments for Resource Allocation Decisions.” 
38 Banta, “The Development of Health Technology Assessment.” 
39 Velasco Garrido, World Health Organization, and European Observatory on Health 
Systems and Policies, Health Technology Assessment and Health Policy-Making in 
Europe: Current Status, Challenges, and Potential. 
40 International Journal of Technology Assessment in Health Care, “Health 
Technology Assessment.” 
41 Velasco Garrido, World Health Organization, and European Observatory on Health 
Systems and Policies, Health Technology Assessment and Health Policy-Making in 
Europe: Current Status, Challenges, and Potential. 
42 Martelli et al., “A Systematic Review of the Level of Evidence in Economic 
Evaluations of Medical Devices.” 
43 Hutton, Trueman, and Henshall, “Coverage with Evidence Development.” 
44 International Journal of Technology Assessment in Health Care, “Health 
Technology Assessment.” 
45 “Iqwig.de – In the HTA Network.” 
46 “EUnetHTA | Health Technology Assessment (HTA).” 
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Figure 2.2-1 by the World Health Organization (WHO) shows the life-cycle 
of a health technology and the different approaches of HTA in the product´s 
life-cycle. HTAs intention is to improve the uptake of new cost-effective tech-
nologies, to avoid the uptake of technologies that can harm humans or are of 
doubtful value for health systems, and to slow down the uptake of technolo-
gies which seem promising but currently have uncertainties.47 
 
Figure 2.2-1: The natural life-cycle of a medical device (adapted from48) 
While HTA is in general reserved for complex problems, the regulatory pro-
cess concerns all medical devices and pharmaceuticals to some degree.49 Table 
2.2-1 gives an overview about the main differences between HTA and regula-
tion. 
Table 2.2-1: Regulation/Approval vs. Reimbursement (adapted from50) 
Characteristics  Health Technology Regulation Health Technology Assessment  
Perspective  Safety and efficacy  Efficacy, effectiveness, and appropriateness  
Requirement  Mandatory  Recommendation in complex technologies  
Role Prevent harm  Maximize clinical and cost effectiveness  
 
The following subchapter provides information about a methodological ap-
proach developed by the EUnetHTA, to assess medical devices in a stand-
ardized manner that facilitates collaboration between HTA-agencies across 
Europe. 
                                                             
47 World Health Organization, Health Technology Assessment of Medical Devices. 
48 Ibid. 
49 Ibid. 
50 Ibid. 
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2.2.1 The HTA CoreModel® 
HTA agencies around the world share a common set of methodological ap-
proaches and principles. However, the structure of HTA reports differs con-
siderably across the agencies because of different national standards, specific 
work processes, and context. This hinders information sharing among HTA 
agencies.51 As a possible solution, the task force Work Package 4 of the EU-
netHTA, consisting of twenty-four organizations from seventeen countries 
and led by the Finnish Office for Health Technology Assessment, developed 
a multidisciplinary common core of Health Technology Assessment evidence, 
the HTA Core Model®.52, 53 
The Core Model® consists of three different parts with specific purposes:  
 The Ontology is a standardized set of HTA questions that allow users to 
define their specific research questions within a hierarchical structure. 
 The Methodological guidance assists and supports in answering the  
research questions.  
 The Reporting structure is a common structure for presenting findings 
in a standardized ‘question-answer pair’ format.54  
The main aim of the HTA Core Model® was to enable collaboration between 
international HTA agencies in producing HTA information, to share the re-
sults in a common and structured format, as well as to avoid redundant work 
in case of similar projects. Besides, the model represents a wide range of dif-
ferent perspectives.55 
The HTA Core Model® consists of nine different domains to assess the di-
mensions of value, as defined in the EUR-ASSESS project: Health problem 
and current use of the technology (implementation level); Description and 
technical characteristics of technology; Safety; Clinical effectiveness; Costs, 
economic evaluation; Ethical analysis; Organizational aspects; Social aspects; 
and Legal aspects.56 
  
                                                             
51 Kristensen et al., “Practical Tools and Methods for Health Technology Assessment 
in Europe.” 
52 Ibid. 
53 Kristensen et al., “European Network for Health Technology Assessment, 
EUnetHTA.” 
54 “EUnetHTA | HTA Core Model®.” 
55 Kristensen et al., “Practical Tools and Methods for Health Technology Assessment 
in Europe.” 
56 Liberati, Sheldon, and Banta, “EUR-ASSESS Project Subgroup Report on 
Methodology. Methodological Guidance for the Conduct of Health Technology 
Assessment.” 
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Table 2.2-2: Domains of the HTA Core Model® 
Domains 
Relative effectiveness 
assessment (REA) 
Comprehensive/  
Full HTA Report 
Health problem and current use of technology 
(implementation level)  
Description and technical characteristics  
Safety  
Clinical effectiveness  
Costs and economic evaluation   
Ethical analysis   
Organizational aspects  
Patient and social aspects  
Legal aspects  
 
A domain, in this context, is a wide framework, representing a perspective 
from which to view the use, consequences and implications of any technolo-
gy.57 Depending on the scope of the assessment, a relative effectiveness as-
sessment (REA) includes the first four domains, a comprehensive/full HTA 
report includes all of the nine domains (Table 2.2-2).58 
The HTA Core Model® consists of 133 assessment elements for medical and 
surgical interventions as well as 153 elements for diagnostic.57, 59 While the 
objective of the HTA Core Model lies on enabling collaboration on the inter-
national level, the envisioned goal is to create a platform that enables trans-
national HTA collaborations between different stakeholders to create a com-
mon pool of structured HTA information.60 
 
2.2.2 Unique characteristics of Medical Devices  
Compared to pharmaceuticals, medical devices have some unique character-
istics that might render the assessment more difficult.  
These characteristics are:  
 Incremental innovation/short lifespan of a device, 
 Learning curve of the device-user (device-operator interaction), 
 Wider economic and organizational implications, 
 Pricing strategy and procurement policies, 
 Heterogeneity of medical devices and class effect, 
 Difficulties in performing experimental studies (e.g. RCTs).61, 62 
                                                             
57 Lampe et al., “The HTA Core Model.” 
58 “EUnetHTA | HTA Core Model®.” 
59 Pasternack et al., “Testing the HTA Core Model.” 
60 Kristensen et al., “Practical Tools and Methods for Health Technology Assessment 
in Europe.” 
61 Drummond, Griffin, and Tarricone, “Economic Evaluation for Devices and Drugs 
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Firstly, in the lifetime of a medical device an incremental (stepwise) techno-
logical innovation takes place. Medical devices evolve very rapidly, sometimes 
within18 to 24 months, and product modifications in delivery systems or re-
duction of their size are common.63 As a result, patients’ benefit might stead-
ily increase over time, but these product modifications can also have negative 
implications on efficacy and other endpoints such as costs.64, 65 This means 
HTA institutes may face evidence of an older version of a medical device once 
the assessment takes place, with a newer version already on the market.66, 67 
Additionally, the short lifespan of medical devices, sometimes shorter than the 
length of clinical tests, makes it hard to obtain clear and useful clinical evi-
dence at one point in time.68 The analyses of clinical studies with different 
versions of medical devices are difficult and retroactively subgrouping can-
not be recommended.69 
Secondly, the learning curve for the use of a medical device depends on the 
device-operator interaction. While drugs are a so-called „embodied technol-
ogy”, meaning as long as given in the right dose the efficacy relates only to 
the drug itself, the device efficacy depends not only on the device itself but 
rather how it is used by the operator (e.g. surgeon or medical professional). 
Errors and adverse outcomes are more likely to occur during the learning 
curve of the operators, which can distort the outcome result of clinical trials. 
After a period of training, the clinician’s experience increases, fewer errors 
occur and the medical device performance improves.70  
Thirdly, the wider economic and organizational implications of the introduc-
tion of medical devices are different in comparison to pharmaceuticals. For 
instance, there might be a need for training of device operators or physicians. 
Alternatively, processes in a hospital must be reorganized to shelter or support 
the new technology.71 Furthermore, the initial and annual (running) costs of 
a medical device must be considered.72 
Fourthly, the price for medical devices constantly changes, resulting from it-
erative improvements of the devices (incremental innovation), market entry 
of new products or different ways of procurement in different health systems. 
                                                                                                                                   
62 Taylor and Iglesias, “Assessing the Clinical and Cost-Effectiveness of Medical 
Devices and Drugs.” 
63 Facey, “HTAi Policy Forum 2015 Background Paper: Improving the Effectiveness 
and Efficiency of Evidence Production for HTA in the Light of Current Trends in 
Drug and Device Development, Health System Funding, Regulation and HTA. 
Edmonton: Health Technology Assessment International; 2015.” 
64 Taylor and Iglesias, “Assessing the Clinical and Cost-Effectiveness of Medical 
Devices and Drugs.” 
65 Sorenson et al., “Applying Health Economics for Policy Decision Making.” 
66 Mowatt et al., “When and How to Assess Fast-Changing Technologies:  
A Comparative Study of Medical Applications of Four Generic Technologies.” 
67 Sorenson et al., “Applying Health Economics for Policy Decision Making.” 
68 Craig et al., “A Review of the Economic Tools for Assessing New Medical 
Devices.” 
69 Parquin and Audry, “Clinical Evaluation of Medical Devices.” 
70 Taylor and Iglesias, “Assessing the Clinical and Cost-Effectiveness of Medical 
Devices and Drugs.” 
71 Ibid. 
72 Ferrusi et al., “Health Technology Assessment from a Canadian Device Industry 
Perspective.” 
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This is dissimilar to pharmaceuticals, where, once the price for the drug is 
negotiated, it is more likely to stay close to that initial price until the patent 
expires.73  
Fifthly, the heterogeneity of medical devices makes them difficult to compare. 
This heterogeneity gets evident when looking at the various applications as 
either diagnostic and therapeutic medical devices. While showing the results 
of a therapeutic device is straightforward, the results of diagnostic devices are 
difficult to separate from the improved patient outcome. Furthermore, some 
of the devices are implantable and need a long-term follow-up. Additionally, 
the diagnostic devices sometimes have multiple applications, which challenges 
the assessment of the total value and health impact of a device, as a weighted 
average value needs to be calculated.74, 75, 76  
Sixthly, the implementation of experimental studies like randomized clini-
cal trials (RCTs) is sometimes more difficult. Some of the aforementioned 
characteristics make it complicated to accomplish a randomized clinical tri-
al. For example, the learning curve of the device operators makes it difficult 
in an RCT to compare a traditional surgical procedure with a new procedure 
involving a device. Further blinding, randomization and the use of sham pro-
cedures for the trials are difficult to apply, and in some cases unethical. Ad-
ditionally, RCTs are often of small sample size because the target population 
is rather small and it is difficult to obtain the patient consent when the RCT 
involves invasive surgical procedures.77, 78 
 
2.2.3 Differentiation to pharmaceuticals  
Medical devices and pharmaceuticals are both meant to improve quality of 
life and are crucial for prevention, diagnosis, and treatment of patients. Yet, 
they are essentially different in their mode of action. While drugs achieve 
their intended action on the human body or in interaction with biochemical 
pathways in the body (pharmacological, immunological or metabolic means), 
medical devices have many different functionalities and modes of action, such 
as heat, mechanical or radiation. Consequently, most of the medical devices 
need an intermediary, the professional for the interaction with patients, while 
drugs interact directly with or in the patient. Another major difference com-
pared to pharmaceuticals is that medical devices are used for therapeutically 
as well as for diagnostic purposes.79, 80 
                                                             
73 Drummond, Griffin, and Tarricone, “Economic Evaluation for Devices and  
Drugs – same or Different?” 
74 Martelli et al., “A Systematic Review of the Level of Evidence in Economic 
Evaluations of Medical Devices.” 
75 Drummond, Griffin, and Tarricone, “Economic Evaluation for Devices and  
Drugs – same or Different?” 
76 Craig et al., “A Review of the Economic Tools for Assessing New Medical Devices.” 
77 Martelli et al., “A Systematic Review of the Level of Evidence in Economic 
Evaluations of Medical Devices.” 
78 Drummond, Griffin, and Tarricone, “Economic Evaluation for Devices and  
Drugs – same or Different?” 
79 Taylor and Iglesias, “Assessing the Clinical and Cost-Effectiveness of Medical 
Devices and Drugs.” 
80 Santos et al., “Medical Device Specificities.” 
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The life-cycle of medical devices and pharmaceuticals varies in different sec-
tors. While the development of a drug takes around a decade to complete, 
the development of a medical device is generally shorter. Figure 2.2-2 shows 
a typical product life cycle of medical devices and pharmaceuticals. Compared 
to pharmaceuticals life cycle, medical devices have faster cycle times because 
of the incremental improvements, which bring essential information and ev-
idence for further device versions.81 
 
Figure 2.2-2: Life-cycle of medical devices and pharmaceuticals (adapted from82) 
Another disparity between medical devices and pharmaceuticals is the indus-
trial development environment. While the majority (95%) of medical device 
industry consists of small- and medium-sized enterprises (SMEs), the pharma-
ceutical industry subsists on a few large companies.83 This circumstance re-
lates directly to the implementation of RCTs, because the performance of RCTs 
is very time-consuming and costly, attributes which SMEs cannot handle eas-
ily. Consequently, less RCTs are conducted or have short follow-ups.84 
Finally, medical devices and pharmaceuticals differ in their pre-market eval-
uation process. While the medical device process is decentralized and handled 
by the competent authorities and their designated Notified Bodies, pharma-
ceuticals licensing and market access is centralized and granted by the Euro-
pean Medicines Agency (EMA). The EMA usually only accepts RCTs for new 
pharmaceuticals, whereas RCTs for medical devices are not feasible in some 
cases.85, 86 
                                                             
81 Ibid. 
82 Ibid. 
83 “MedTech Europe.The European Medical Technology Industry in Figures 2015.” 
84 Craig et al., “A Review of the Economic Tools for Assessing New Medical Devices.” 
85 Taylor and Iglesias, “Assessing the Clinical and Cost-Effectiveness of Medical 
Devices and Drugs.” 
86 Tsoi et al., “Harmonization of Reimbursement and Regulatory Approval Processes.” 
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3 Methods 
The data collection for this research is divided into two main parts: the first 
part collected and analyzed information on Health Technology Assessment 
(HTA) for medical devices in Europe and the critical points discussed in the 
literature compared to pharmaceuticals. The second part focused on accessi-
ble information to discover similarities between European Health Technolo-
gy Assessment institutes in the context of the assessment of medical devices, 
and the used evidence compared to the year of the CE-mark.  
 
 
3.1 Research questions 
This research project aims at contributing to the efforts towards a stronger 
collaboration of European HTA institutes. The research questions are focus-
ing on the critical points and challenges in the assessment of medical devic-
es and procedures as well as the comparison of different HTA institutes and 
their reports regarding the used evidence and timing:  
 Which critical points in the assessment of medical devices and  
procedures were discussed in the recent literature?  
 Which high-risk medical devices have been assessed in Europe  
at a specific time by using varying evidential information?  
 Is there a possibility to group (cluster) HTA institutes according  
to timing (time between CE-mark and early or late HTAs)? 
 
 
3.2 Literature Review  
A systematic literature search was conducted in Medline via PubMed. The 
literature search was supplemented by hand searches („informed electronic 
browsing”) in search engines (e.g. google) and screening of the references cited 
in the documents previously identified (i.e. cross-referencing). All search out-
comes were documented and underwent a selection process. Predefined in-
clusion and exclusion criteria guided the literature selection process. All rel-
evant steps are documented in a PRISMA-tree. The main inclusion and ex-
clusion criteria are represented in Table 3.2-1.  
The following keywords were used during the literature search: 
Health Technology Assessment* AND HTA* AND Technology Assessment, bio-
medical [MeSH Terms] AND equipment and supplies [MeSH Terms] AND 
medical devices* AND medical instruments* AND Europe* AND EU* AND 
European Union* AND Regulation* AND Characteristics* AND Reimburse-
ment* AND Classification* AND Harmonization* AND Policy-making* AND 
Impact* AND Influence* AND Timing* AND Challenges* 
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Table 3.2-1: Inclusion and exclusion criteria for literature review 
Inclusion criteria Exclusion criteria 
 In English and German language  
 European HTA agencies only 
 Articles about medical devices, 
procedures, and technologies  
 Critical points of European HTA  
 Publications available from 2010 
until August 2016 
 Full articles with abstracts 
 Only abstracts 
 HTA agencies outside of Europe 
 Articles mainly about 
pharmaceuticals 
 Other languages  
 
The PRISMA-tree (see Figure 3.2-1) shows the documentation of the relevant 
steps to identify the literature used in the review.  
 
Figure 3.2-1: PRISMA-tree for the documentation of the literature search 
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3.3 Analysis of European HTAs on selected 
medical devices 
The data collection for this section is (partially) based on a database devel-
oped in the EU-FP7 (2007-2013 under grant agreement No. 305983) project 
ADVANCE_HTA (Advancing and strengthening the methodological tools 
and policies relating to the application and implementation of Health Tech-
nology Assessment). The database consists of all HTA reports conducted 
from 2004 till 2015 by European HTA institutes and are classified by their 
taxonomic position.  
As a first step, a cohort group of all HTA reports conducted in 2014 was se-
lected from the database. Then, the inclusion criteria for further processing 
of the 2014 cohort group was defined: all class 2b, 3 (high-risk) or active im-
plantable medical devices (class 4) by the ADVANCE_HTA taxonomic posi-
tion. To identify the risk class of each of the data records, a matrix devel-
oped by the EU-FP7 project ADVANCE_HTA was used (Table 3.3-1).  
Table 3.3-1: Matrix of taxonomic position and risk classes (adapted from87) 
Classification 
criteria of  
EU-Directives 
according to 
risk aspects 
Classification according to the relevance of product & service and reimbursement characteristics 
(includes OECD Classification of Health Care Functions) + HTA logic 
Diagnostic Technologies Therapeutic Technologies 
Assistive 
technology 
devices 
(directly used 
by patients) 
A1 
Artificial  
body parts 
(implanted  
by medical 
procedure) 
B1 
Medical 
devices for  
the assistance 
of medical 
professionals 
C1 
Assistive 
technology 
devices 
(directly used 
by patients) 
A2 
Artificial  
body parts 
(implanted  
by medical 
procedure) 
B2 
Medical 
devices for  
the assistance 
of medical 
professionals 
C2 
93/42/ 
EEC 
1 Thermometer  Stethoscope Walking frame  Spatula 
2a Pulse oximeter  Ultrasound Hearing aid Dental crown Tracheal tube 
2b   
X-ray,  
PET-CT 
Insulin pen; 
Corrective 
lenses 
Dental 
implant; Bone 
prosthesis 
Laser  
RT-Unit 
3   
Neuro-
endoscope 
Condoms with 
spermicide 
Cardiac stents; 
Artificial joints 
Angioplasty 
balloon 
catheter 
90/385/ 
EEC 
4  
ICD:  
heart monitor 
unit 
  
ICD: 
defibrillator 
unit 
 
98/79/ 
EC 
5 
Glucose strip; 
pregnancy test 
 
ABO/Rh (D) 
blood analyzer 
   
 
Based on the classification of this matrix, n = 87 HTA reports of high-risk 
medical devices in 2014 were identified (full list of the 87 reports in Appen-
dix Table 8-1). Out of these 87 reports, ten topics (medical procedures or de-
vices) were chosen for further processing.  
                                                             
87 Fuchs et al., “Testing the Plausibility of a Taxonomy for Medical Devices in the 
Logic of HTA: Poster Presentation HTAi Oslo;2015.” 
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For the ten chosen topics from 2014, a further literature search was conduct-
ed to find HTA reports by other institutions in years before and after 2014. 
For this step, the University of York’s Centre for Reviews and Dissemination 
(CRD-)HTA database, as well as the commercial Synergus database were ana-
lyzed. The inclusion and exclusion criteria for this search were represented 
in Table 3.3-2. 
Table 3.3-2: Inclusion and exclusion criteria for further HTA report search  
Inclusion criteria Exclusion criteria 
 All languages of the European HTA agencies  
 HTA reports and rapid assessments 
 Agencies outside of Europe 
 Just abstracts  
 clinical evidence used is clearly described  clinical evidence used is 
unclear 
 
In this search, 109 different HTA reports regarding the ten topics selected 
were identified in CRD and Synergus. Out of the 109 reports a comprehen-
sive pool of four reports per topic (medical procedure or device) were chosen 
for detailed data collection. The 109 reports were scanned and four reports 
were chosen for each topic for further analysis. A pre-defined in-/exclusion 
criterion for the selection of the four HTA reports was the clear presentation 
of the clinical evidence used. These reports underwent a second, more thor-
ough examination. The second examination focused on the evidence used in 
the process of conducting the HTA reports. In a final step, the year of CE-
mark of the medical devices was searched in literature and in in the world-
wide web.  
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4 Results 
4.1 Literature Review: Critical Points in 
Assessing Medical Devices in Europe 
Critical arguments in the assessment of medical devices are brought into the 
public discussion from several perspectives (from different stakeholders and 
their points of view). 
These key stakeholders are:  
 Patients,  
 Health Management,  
 The Health Professionals, 
 Industry, 
 Payers and Insurances, 
 Regulators and Government.88, 89 
In the recent literature, several different critical points in assessing medical 
devices are discussed. Those points can be attributed to some of the stake-
holders mentioned above. Figure 4.1-1 provides an overview of the different 
themes that cause challenges in the assessment of medical devices. 
 
Figure 4.1-1: Critical points in assessing medical devices in Europe 
In the following, each subchapter captures one of the critical points shown above 
and explains the circumstances why and how those points are challenging.  
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4.1.1 Critical Point: Missing of robust evidence 
HTA institutes are frequently confronted with the missing of high-level clin-
ical evidence, while they should assess new innovative medical devices on the 
best evidence available.90 When HTA institutes assess the value of health 
technologies, the existence of relevant and robust clinical data regarding ef-
ficacy, safety and effectiveness is of high importance. While for pharmaceu-
ticals much of the clinical data available is generated to demonstrate efficacy 
and safety to the regulator, clinical data for medical devices is very limited, 
especially at the time of product launch. This is a result of the different reg-
ulatory frameworks in the various jurisdictions and is a consequence of the 
eventual difficulty in conducting relevant clinical trials.91, 92  
In addition, the regulatory process of medical devices generally targets prod-
uct safety and function. However, the required evidence depends on the med-
ical devices risk-level to which the patients are exposed. Despite these rules 
for evidence requirements, for many products trials to create clinical evidence 
are not required or the trials were conducted by the manufacturer.93 This 
leads to the huge variation between the evidence requirements for market 
authorization and reimbursement (HTA).94 
One of the views on the European medical device regulatory system is that it 
is „opaque and patchy” – as expressed in a debate in the US Congress. The 
medical device industry perceives Europe as more favorable than most of the 
other economic regions like the United States or Australia.95 The liberal reg-
ulatory framework in Europe has supported the growth of the medical device 
industry.96 Despite the better conditions for the device industry, most of the 
HTA-institutes assume that it is not better for patients. Although there are 
agreed European standards like the MDD or AIMDD, concerns were raised 
that these standards are not applied or fully performed. This leads to the as-
sumption that some of the organizations, designated to control market entry 
in Europe, are not rigorous enough in auditing safety or performance of the 
devices.97 Coverage bodies are aware that most of the evidence generated by 
the manufacturers meets the regulatory requirements, but is not sufficient to 
satisfy the evidence requirements of HTA.98  
                                                             
90 Hulstaert et al., “Pre-Market Clinical Evaluations of Innovative High-Risk 
Medical Devices in Europe.” 
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96 Sauerland et al., “Approaches to Assessing the Benefits and Harms of Medical 
Devices for Application in Surgery.” 
97 Cohen and Billingsley, “Europeans Are Left to Their Own Devices.” 
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The results of a recently conducted cohort study support this hypothesis, be-
cause the devices studies were approved first in the EU and showed a higher 
risk of post-marketing safety alerts as well as recalls.99, 100 These results are 
supported by another study that investigated seven medical devices author-
ized in four economic regions (Europe, United States, Canada, Australia). The 
results show that only in Europe all seven devices were approved, while three 
were approved in Australia, and only one in Canada and the United States.101 
Furthermore, considering the time of CE-marking of those seven devices in 
comparison to the time needed to develop robust clinical evidence (e.g. RCTs), 
the CE-mark is granted several years before robust clinical data is availa-
ble.102 This supports the statement that many devices received the CE-mark 
on the evidence base of case series with around 50 cases.103 
 
4.1.2 Critical Point: Methodology applied 
In the last decade, a great variety of new and highly developed medical devices 
has emerged.104 These devices bring therapeutic and diagnostic advantages, 
but they also shed light on emerging methodological challenges regarding 
their assessment. Since most of the methodological guidelines have been de-
veloped to suite the assessment of pharmaceuticals, these methods are diffi-
cult to apply for medical devices.105  
In the context of ill-fitted methodology, some of the major methodological 
challenges for the assessment of medical devices are related to their unique 
characteristics and were mentioned afore, such as the potentially high learn-
ing curve (device-user interaction) or incremental and dynamic innovation.106 
Medical devices are often associated with a learning curve because the users’ 
training and skills can have an important impact on the devices’ performance, 
which is hard to include and measure in the assessment with the current 
methodological tools. Further, the learning curve influences the cost-effec-
tiveness of the medical devices.107, 108 The rapid pace of the advancement of 
medical devices leads to more incremental innovation, rather than new break-
through technologies. This step-by-step innovation poses specific methodo-
logical hurdles for the assessing medical devices.109  
                                                             
  99 Hwang et al., “Comparison of Rates of Safety Issues and Reporting of Trial Out-
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Value-Based Regulation of Medical Devices in Europe.” 
101 Krüger et al., “Divergent Evidence Requirements for Authorization and 
Reimbursement of High-Risk Medical Devices – The European Situation.” 
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104 Dhruva and Redberg, “Medical Device Regulation.” 
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106 Schnell-Inderst et al., “Health Technology Assessment of Medical Devices.” 
107 Tarricone et al., “Generating Appropriate Clinical Data for Value Assessment of 
Medical Devices.” 
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Moreover, the differentiation between therapeutic and diagnostic devices 
comprises challenges for the methodology. The value of improved diagnosis 
through the new device cannot be separated from the overall treatment suc-
cess.110 Furthermore, some indirect and broader aspects of assessing the im-
pact of the device on productivity or the caregivers quality of life are men-
tioned in the literature as methodological challenges.111, 112 In addition, the 
assessment of the long-term outcome of diagnostic devices contains challeng-
es for the methodology, because the result of a diagnostic device can improve 
diagnosis, but this outcome is difficult to measure.113, 114  
 
4.1.3 Critical Point:  
Harmonization of HTA requirements 
In contrast to the pharmaceutical sector, the HTA processes and regulations 
around medical devices are less harmonized within the EU. The coordina-
tion between national pharmaceutical regulators and the centralized Euro-
pean Medicines Agency (EMA) as well as the evidence requirements for cov-
erage in benefit catalogues is well defined and established.  
In contrast, the medical device regulators have some similarities in their in-
formation requirements, but their international coordination is less devel-
oped compared to pharmaceuticals.115 The harmonization of requirements 
for Health Technology Assessment is even less developed. This harmoniza-
tion covers three different areas:  
„(i) harmonization of approaches and processes;  
(ii) harmonization of methods and evidence requirements;  
(iii) harmonization of decisions”116. 
Many new developments have been made in order to harmonize the methods 
for HTA assessments on medical devices; less focus was set on harmonized 
approaches and decision making. This can partially be attributed to politics 
since coverage and reimbursement decisions are subject to individual coun-
tries decision making.117  
A review on the basis of 21 economic evaluation suggested that there is a 
wide variety of methods used as well as a huge difference between the quali-
ty of evidence used to perform analyses.118 Some of the technologies are as-
sessed multiple times by different institutes which has a strong influence on  
                                                             
110 Drummond, Griffin, and Tarricone, “Economic Evaluation for Devices and 
Drugs – same or Different?” 
111 Sorenson et al., “Applying Health Economics for Policy Decision Making.” 
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115 Henshall et al., “Interactions between Health Technology Assessment, Coverage, 
and Regulatory Processes.” 
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the institute’s human and financial resources.119, 120 Therefore, a better com-
munication and coordination could reduce discrepancies regarding the evi-
dence requirements and consequently improve the efficiency of the review 
process.121  
A further example of a lack of harmonization is the definition of medical de-
vices itself. Even though there is a Council directive outlined by the European 
Parliament which defines medical devices, numerous additional definitions 
of medical devices exist and vary from country to country as well as their clas-
sification of risk-classes.122, 123, 124  
 
4.1.4 Critical Point: Impact on decisions 
The impact of Health Technology Assessment on decision making depends 
on the legally binding requirements of the jurisdiction. Some of the institutes´ 
recommendations are binding for the reimbursement agency, while other in-
stitutes’ reports only have a supporting or advising function.125 A study con-
ducted by the Austrian LBI-HTA concerning the impact of HTA reports on 
reimbursement of new hospital interventions found, that the majority of their 
reports have been used in decision processes regarding reimbursement/in-
vestment or disinvestment, although the LBI-HTA only has an advisory func-
tion.126  
Another study, which surveyed 16 HTA institutes of 14 European countries, 
confirmed these results, suggesting that many institutions consider their as-
sessments to have an impact on the decision and policy-making process.125 
The Swedish HTA institute SBU conducted a study concerning the effect of 
their Health Technology Assessment reports on policy-making and clinical 
practice. Therefore, 26 conducted reports between 2006 and 2010 were ana-
lyzed and the level of impact scored (low, moderate, high). The results showed 
that the HTA reports influence comprehensive decisions and on national 
guidelines.127  
Nonetheless, the monitoring of HTA impact is difficult because most assess-
ments produced by the institutes are not binding for the decision-making 
process. Moreover, the impact relies on the level (e.g. national, regional) to 
which the HTA report was formulated for.125 
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4.1.5 Critical Point: Timing of assessments 
The timing for conducting an assessment is crucial, due to the lack of clearly 
defined and publicly available market authorization decisions valid through-
out Europe, the absence of a clear point of market entry, as well as the exist-
ence of robust clinical data. For the coverage bodies, assessments are relevant 
and should be available at the time when the reimbursement and coverage de-
cisions take place.  
Therefore, the timing of the assessment is key. If the assessment happens at 
a late stage of the medical device life cycle, the decision for or against reim-
bursement might already be obsolete, since a decision has to be made close to 
the device’s introduction to the market. If the assessment is conducted too 
early, it is likely that there is not enough robust clinical evidence available to 
make a clear decision without uncertainty.128, 129 
 
 
4.2 Analysis: Comparison of European  
HTAs on same Technologies  
This chapter will give an overview on and insights into the differences be-
tween European HTAs of selected medical devices in consideration of the 
timing of the assessment and the clinical evidence used. The following infor-
mation was essential for the comparison:  
 Year of obtaining the CE-mark of the technology 
 Year of conducting the HTA report 
 The clinical evidence used for performing the assessment 
Therefore, ten different technologies and procedures were chosen based on 
their frequency of assessment in Europe and for each of them, four reports 
were selected for further analysis. The mentioned HTA reports were found 
through multiple searches in databases and search engines. Moreover, the date 
of CE-mark was searched on the manufactures website as well as the world-
wide web for announcements regarding the CE-mark.  
In the following sections, the results for the ten technologies and procedures 
are presented: first, the indication and procedure of the medical device is ex-
plained, secondly, the ten high-risk devices and their respective assessments 
are presented  
 
4.2.1 Implantable cardiac resynchronization 
therapy and defibrillator (CRT: CRT-D/CRT-P) 
Several cardiac diseases such as myocardial infarction or heart valve disorders 
weaken the heart and negatively impact the ability to pump blood to the rest 
of the body. The resulting state is called a heart failure. Usually, heart failure 
                                                             
128 Schnell-Inderst et al., “Health Technology Assessment of Medical Devices.” 
129 Tarricone et al., “Generating Appropriate Clinical Data for Value Assessment of 
Medical Devices.” 
lack of publicly available 
approval decisions = 
absence of clear market 
entry at one point  
in time 
timing of HTA:  
before diffusion  
comparison with regard 
to proximity to CE-mark 
and clinical evidence 
used in assessments 
10 technologies selected 
based on frequency of 
HTAs in Europe 
structure of  
following chapters 
indication and 
procedure 
Results 
LBI-HTA | 2016 35 
develops stepwise, depending on the severity of the underlying cardiac disease. 
A healthy heart has a well-coordinated pumping cycle that can be damaged 
by heart failure, causing an unsynchronized contraction of the ventricles. The 
cardiac resynchronization therapy and defibrillator is a method aiming to syn-
chronize the action of the heart in order to improve the heart’s ability to pump. 
Currently, pacemaker stimulation of the right atrium and ventricle for treating 
a slow pulse rate (bradycardia) is the common and well-established therapy. 
For the cardiac resynchronization therapy, an additional electrode over the 
left ventricle is placed, to synchronize the contraction of both ventricles.130 
Between 2003 and 2015, nine HTA institutes assessed CRT technology in 11 
HTA reports. Of those 11, four were selected for an analysis of the evidence 
used, displayed in Table 4.2-1. In addition a short form (a, b, c, d) is assigned 
in order to locate the respective report in the evidence pyramid presented in 
the appendix (see Figure 8-1). The first CRT technology received the CE-
mark in 2001. The manufacturer of this technology was the Guidant Corpo-
ration with the heart failure therapy system CONTAK™ RENEWAL™ car-
diac resynchronization therapy defibrillator (CRT-D).131 The CRT technol-
ogy is comprising a multitude of different devices (CRT-P, CRT-D) from dif-
ferent manufacturers and generations of devices.  
Table 4.2-1: Summary of HTA institutes that conducted reports on CRT-D/CRT-P 
Institute Country Year of report Short form 
SBU Sweden 2003 a 
HIS Scotland  2005  
KCE Belgium 2007  
NIHR England 2007  
AETSA Spain 2009 b 
UETS Spain  2010  
KCE Belgium  2011  
AGENAS Italy 2014 c 
NIHR England 2014  
NICE England 2014  
Swiss Medical Board Switzerland  2015 d 
 
The first HTA in 2003 (SBU), 2 years after the receipt of the CE-mark, was 
based on seven RCTs. The HTA conducted in 2009 (AETSA) is already based 
on systematic reviews, 17 RCTs and seven clinical practice guideline. The 
HTA conducted in 2014 (AGENAS) used the evidence of eight systematic re-
views and meta-analysis, and additional 34 primary comparative studies. The 
latest HTA in 2015 by the Swiss Medical Board, is based on nine meta-anal-
yses and five randomized clinical trials (see Table 4.2-2 below and Figure 8-1 
in Appendix).  
The minimum level of evidence used in the four analyzed HTAs is compara-
tive trials and randomized clinical trials, revealing a high level of clinical ev-
idence at time of HTAs. The first assessment after CE-mark (2001) was con-
ducted 2 years after (2003) the market approval.  
                                                             
130 SBU, “Cardiac Resynchronization Therapy (CRT) in Chronic Heart Failure.” 
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Table 4.2-2: Summary of information of 4 HTA reports on CRT-D/CRT-P 
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Implantable 
cardiac 
resynchronization 
therapy and 
defibrillator  
(CRT-P, CRT-D) 
Pacemaker fo ̈r 
synkronisering av 
hja ̈rtkamrarnas 
rytm (CRT) vid 
kronisk hja ̈rtsvikt 
SBU 2003 2001 7 RCTs http://bit.ly/2bOEb2h 
Standards for 
health technologies 
appropriateness: 
Cardiac 
resynchronization 
therapy 
AETSA 2009 7 systematic reviews/ 
meta-analysis 
17 randomized 
clinical studies 
7 clinical practice 
guidelines 
http://bit.ly/29KrisN 
Implantable cardiac 
resynchronization 
therapy and 
defibrillator (CRT-D) 
in patient with 
heart failure  
AGENAS 2014 8 systematic reviews/ 
meta-analysis 
34 primary 
comparative studies  
http://bit.ly/29Jzc48 
Le stimulateur 
cardiaque de 
resynchronisation 
dans le traitement 
de l’insuffisance 
cardiaque  
Swiss 
Medical 
Board 
2015 9 meta-analysis 
5 RCTs  
http://bit.ly/29AJ4fx 
 
4.2.2 MitraClip® 
Mitral regurgitation is described as the state in which a backward flow of blood 
from the left ventricle to the left atrium during the contraction phase of the 
cardiac cycle (systole) takes place. The underlying reason is the dysfunction 
of the mitral valve to close entirely. Usually, the mitral valve opens to fill the 
ventricle with blood from the atrium and closes automatically due to the 
pressure in the ventricle, while the blood is pushed out to the aorta. Because 
of the insufficient closure of the valve, blood streams back to the atrium and 
the pressure in the left atrium increases. Over time, this can lead to a growth 
of the left atrium. In severe cases of mitral regurgitation, the blood accumu-
lates back into the lung. Additionally, the performance of the left ventricle is 
weakened. If left untreated, severe mitral regurgitation can result in a heart 
failure and potentially lead to death. The implantation of the MitraClip® on-
to the valve leaflets forms two smaller orifices allowing improved valve clo-
sure and reduced leakiness.132, 133 The MitraClip® procedure is performed 
through a venous access, avoiding open-heart surgery and cardiopulmonary 
bypass.  
Between 2010 and 2016 the MitraClip® procedure was assessed by seven HTA-
institutes in nine reports. Of those nine reports, four were selected for an anal-
ysis of the evidence used. The results are displayed in Table 4.2-3. In addi-
tion a short form (a, b, c, d) is assigned in order to locate the respective re-
port in the evidence pyramid presented in the appendix (see Figure 8-2). 
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The MitraClip® is developed and produced by Abbott and received the CE-
mark first in 2008.134  
Table 4.2-3: Summary of HTA institutes that conducted reports on MitraClip®  
Institute Country Year of report Short form 
LBI-HTA Austria  2010 a 
LBI-HTA Austria 2012  
Stockholm County Council 
HTA Center 
Sweden 2012 b 
CEDIT France  2012  
AOTMIT Poland  2013  
OSTEBA Spain  2014 c 
HAS France 2015 d 
LBI-HTA Austria  2015  
HIS Scotland  2016  
 
The first HTA was conducted in 2010 (LBI-HTA), 2 years after receiving the 
CE-mark, and is based on one prospective, uncontrolled before-after study. 
An update in 2012 included one RCT and ten prospective, uncontrolled stud-
ies. Another HTA in 2012 (Stockholm County Council HTA-Center) based 
their decision on one prospective multicenter single arm study, one random-
ized multicenter study and ten observational studies. The third selected HTA 
in 2014 (OSTEBA) was based on one systematic review, two RCTs, and nine 
case series. The latest selected HTA was conducted in 2015 (HAS) and used 
one prospective multicenter randomized study and nine non-comparative co-
hort studies (see Table 4.2-4 below and Figure 8-2 in Appendix).  
The minimum level of evidence used in the analyzed HTAs ranges from ob-
servational studies to uncontrolled trials, revealing a mid-level of clinical ev-
idence at time of HTAs. The first assessment after CE-mark (2008) was con-
ducted 2 years after (2010) the market approval.  
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Table 4.2-4: Summary of information in 4 HTA reports on MitraClip®  
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
MitraClip® Perkutane Mitral-
klappenintervention 
mittels MitraClip bei 
Mitralklappen-
insuffizienz  
LBI-HTA 2010 
2012 
2008 2010 
1 prospective, 
uncontrolled  
before-after study 
2012 
1 RCT 
10 prospective, 
uncontrolled studies  
http://bit.ly/29Ub4Nh 
http://bit.ly/29AUrqy 
MitraClip® Stockholm 
County 
Council 
HTA Center 
2012 1 prospective,  
multicenter single 
arm study 
1 randomized 
multicenter study 
10 observational 
studies (2 multicenter; 
5 prospective) 
http://bit.ly/29LNzU9 
Using MitraClip® to 
repair mitral valve 
regurgitation  
OSTEBA 2014 1 systematic review 
2 RCTs  
9 uncontrolled trials 
http://bit.ly/29A2ynp 
Evaluation d’un clip  
de réparation mitrale 
bord à bord et de son 
acte d’implantation  
HAS 2015 1 prospective, 
multicenter, 
randomized study 
9 non-comparative 
cohort studies 
http://bit.ly/1Q1h5CN 
 
4.2.3 Intensity-modulated radiation therapy (IMRT) 
The intensity-modulated radiation therapy is a sophisticated technology of 
high-precision radiotherapy. Via computer-controlled linear accelerators, the 
radiation doses are transported to a malignant tumor or specific areas within 
the tumor. IMRT is able to transport the radiation dose more precisely to the 
three-dimensional (3-D) shape of the tumor by regulating the intensity of the 
radiation beam in multiple small volumes. In addition, IMRT allows also the 
use of higher doses of radiation within the tumor, while minimizing the dose 
to the surrounding normal tissue. The treatment is planned with 3-D comput-
ed tomography (CT) or magnetic resonance images (MRI) of the patient as well 
as computerized dose calculations to determine which dose fits best. Currently, 
the IMRT is used to treat prostate, head and neck, lung and breast cancer.135  
The IMRT technology was assessed in 11 HTA reports by eight institutes be-
tween 2003 and 2015. For a further analysis of the evidence used, four reports 
were selected (blue-colored rows). The results of this analysis are presented 
in Table 4.2-5. In addition a short form (a, b, c, d) is assigned in order to locate 
the respective report in the evidence pyramid presented in the appendix (see 
Figure 8-3).The IMRT technology was first introduced on the European mar-
ket by the NOMOS Corporation under the name Peacock® system, unfor-
tunately, the year of CE-mark is not accessible or has not been published.136 
The IMRT technology is comprising a multitude of different devices from 
different manufactures, generations of devices and scope of application.  
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Table 4.2-5: Summary of HTA institutes that conducted reports on IMRT 
Institute Country Year of report Short form 
NIHR England 2003  
AVALIA-T Spain  2005 a 
HAS France 2006  
KCE Belgium  2007 b 
NIHR England 2010 c 
AETSA Spain 2010  
ASSR Italy 2010  
KCE Belgium  2013  
OSTEBA Spain  2014 d 
OSTEBA Spain  2014  
HAS France 2015  
 
The first selected HTA on IMRT in 2005 (AVALIA-T) was based on two dif-
ferent indications: on prostate cancer based on evidence from one retrospec-
tive study and two retrospective case series and on head and neck cancer based 
on evidence from one retrospective case series. The HTA by the Belgian KCE 
(2007) includes three different indications ranging from head and neck cancer 
to prostate cancer and breast cancer. For head and neck cancer one RCT, six 
retrospective comparisons, and two prospective studies were included, while 
for prostate cancer six retrospective comparisons were used. The indication 
breast cancer was based on one RCT and one retrospective comparison. The 
NIHR (2010) conducted their report only on prostate cancer with the evidence 
used in four systematic reviews and eight comparative studies of which five 
were retrospective patient records and three were prospective comparisons. 
The HTA from the Spanish OSTEBA (2014) conducted their report on pros-
tate (six studies), head and neck (five studies), breast (3 studies) and lung can-
cer (2 studies). All the studies included were observational prospective stud-
ies (see Table 4.2-6 below and Figure 8-3 in Appendix).  
The minimum level of evidence used in the analyzed HTAs was retrospec-
tive case series and retrospective comparisons (low level of evidence). Since 
the year of CE-mark is not known, no information can be provided on the 
proximity of the first assessment to market approval. 
  
detailed analysis of  
4 HTA reports 
 
2005 (2 indications): 
retrospective case-series 
2007 (3 indications):  
1 RCT + retrospective + 
prospective comparisons 
2010 (1 indication):  
4 SR + 8 retrospective + 
prospective comparisons 
2014 (4 indications): 
prospective case-series 
minimum:  
retrospective case series 
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Table 4.2-6: Summary of information in 4 HTAs on IMRT 
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Intensity-
modulated 
radiation 
therapy 
(IMRT) 
Radioterapia  
de intensidad 
modulada 
AVALIA-T 2005 - Prostate cancer 
1 retrospective study 
(review of medical records) 
2 retrospective case series  
Head/Neck cancer 
1 retrospective case series  
http://bit.ly/29MCCRL 
Intensity-
modulated 
radiotherapy 
(IMRT) 
KCE 2007 Head/Neck cancer 
1 RCT 
6 retrospective comparisons 
2 prospective studies 
Prostate cancer 
6 retrospective comparisons 
Breast cancer 
1 RCT 
1 retrospective comparison 
http://bit.ly/29Bcjwk 
Intensity-
modulated 
radiotherapy for 
the treatment of 
prostate cancer 
NIHR 2010 Prostate cancer 
4 systematic reviews 
8 comparative studies 
(5 retrospective patient 
records;  
3 prospective comparisons) 
http://bit.ly/29O79i9 
An evaluation  
of intensity-
modulated 
radiotherapy 
(IMRT) 
OSTEBA 2014 Prostate cancer 
6 studies  
Head/neck cancer 
5 studies  
Breast 
3 studies 
Lung cancer 
2 studies  
studies = observational 
prospective studies 
http://bit.ly/29MCzFO 
 
4.2.4 High intensity focused ultrasound (HIFU) 
The high intensity focused ultrasound technology is a cancer treatment, which 
works with high-frequency sound waves. These bundled sound waves deliver 
a strong beam to a specific part of defined tissue and heat it up between 90 
and 100 degrees Celsius for a maximum of three seconds. This leads to the 
death of tumor cells. HIFU can be used for single tumors and parts of large 
tumors, however, HIFU cannot be used for tumors that have spread through-
out the patient’s body. The advantage of this type of treatment is the less fre-
quent occurrence of side effects, compared to the side effects of other cancer 
treatments. The HIFU treatment can be used for prostate, kidney, liver, pan-
creatic and bladder cancer.137 138 
                                                             
137 “High-Intensity Focused Ultrasound, HIFU – Clinic for Prostate Therapy 
Heidelberg.” 
138 UK Cancer Research, “High Intensity Focused Ultrasound (HIFU).” 
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Table 4.2-7: Summary of institutes which conducted reports on HIFU 
Institute Country Year of report Short form 
NIHR England  2003  
NICE England 2005 a 
UETS Spain  2007  
IQWIG Germany  2009  
HAS France  2010  
LBI-HTA Austria  2010 b 
AQuAS Spain  2010  
G-BA Germany  2010  
AGENAS Italy  2011 c 
AETSA Spain  2013  
ZIN  Netherlands 2013  
AOTMIT Poland 2014 d 
 
Between 2003 and 2014 twelve HTA reports by twelve different institutes were 
conducted on the HIFU technology. Of those twelve, four reports were select-
ed for an analysis of evidence used. The results are presented in Table 4.2-7. 
In addition a short form (a, b, c, d) is assigned in order to locate the respective 
report in the evidence pyramid presented in the appendix (see Figure 8-4). 
The first HIFU device was CE-marked in 1999/2000 by the manufacturer 
EDAP TMS and is called Ablatherm® HIFU.139 HIFU can be used for the 
treatment of several cancer types, but the selected reports are exclusively fo-
cused on prostate cancer.  
The first selected HTA in 2005 (NICE), 5 years after the CE- mark, was based 
on one systematic review, which included 8 case series studies. The second 
selected HTA by the LBI-HTA (2010) included 20 prospective, uncontrolled 
case series to make a decision. One year later in 2011, the Italian AGENAS 
conducted a HTA based on two systematic reviews, 23 observational case se-
ries (not randomized or comparative) and three HTA reports by other insti-
tutes. The latest selected HTA by the Polish institute AOTMIT (2014) based 
their decision on 15 systematic reviews, five clinical trials and ten case-series. 
Most studies included were observational prospective case-series (see Table 
4.2-8 below and Figure 8-4 in Appendix).  
The minimum level of evidence used in the analyzed HTAs was uncontrolled 
and observational retrospective case series, revealing a rather low level of clin-
ical evidence at time of HTAs.  
  
                                                             
139 EDAP TMS, “High Intensity Focused Ultrasound (HIFU).” 
all HTA reports 
evidence used in HTAs 
 
12 reports 2003-2014 
detailed analysis  
of 4 HTAs: 
 
2005: 4 SR of  
8 case-series 
2010: 20 case-series 
2011: 2 SR of  
23 case-series 
2014: 15SR + 5CT +  
10 case-series 
minimum:  
retrospective case-series 
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Table 4.2-8: Summary of information of 4 HTA reports on HIFU 
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
High 
intensity 
focused 
ultrasound 
(HIFU) 
High intensity focused 
ultrasound for prostate 
cancer 
NICE 2005 1999/ 
2000 
1 systematic review 
(including 8 case 
series studies)  
http://bit.ly/29JB5O7 
Hochintensiver 
fokussierter Ultraschall 
(HIFU) zur Behandlung 
des Prostatakarzinoms 
LBI-HTA 2010 20 prospective, 
uncontrolled case 
series  
http://bit.ly/29O7u4C 
Trattamento del 
carcinoma della prostata 
mediante termoablazione 
con HIFU 
AGENAS 2011 2 systematic reviews  
23 observational case 
series (not randomized 
or comparative) 
3 HTAs 
http://bit.ly/2a4KGNr 
 
4.2.5 Lumbar total disc replacement  
The human spine includes 33 vertebrae grouped according to their location: 
7 cervical (numbered C1-C7), 12 thoracic (T1-T12), 5 lumbar (L1-L5), 5 sacral 
(S1-S5) and four coccygeal vertebrae. While the last two groups, sacral and 
coccygeal, are fixed, the other three groups are so-called moveable. Between 
C2 to S1, an intervertebral disc separates the vertebrae. These discs are flex-
ible and responsible for absorbing shock and ensure the spine movement and 
stability. The most affected parts of the spine are the cervical and the lumbar 
spine. When the lumbar spine is affected by degenerative disc disease (DDD), 
the most common symptom is lower back pain. As a treatment, first conserva-
tive and without any improvement a discectomy is recommended. A possible 
alternative is a total disc replacement, in which the natural disc is replaced 
by a non-rigid artificial disc prosthesis without fastening the vertebrae togeth-
er, as it is made in a discectomy.140  
Table 4.2-9: Summary of institutes which conducted reports on lumbar total disc replacement  
Institute Country Year of report Short form 
HAS France 2007 a 
NICE England  2009  
LBI-HTA Austria  2010 b 
Metodrådet i Sydöstra Sjukvårdsregionen  Sweden  2013  
AETSA Spain  2014 c 
KCE Belgium  2015 d 
Swiss Medical Board Switzerland 2015  
AGENAS Italy 2016  
 
Between 2007 and 2016 eight HTA institutes assessed the lumbar total disc 
replacement procedure. Of those eight, four reports were selected for an anal-
ysis of evidence used. The results are displayed in Table 4.2-9. In addition a 
short form (a, b, c, d) is assigned in order to locate the respective report in 
the evidence pyramid presented in the appendix (see Figure 8-5). 
                                                             
140 “KCE | Cervical and Lumbar Total Disc Replacements | HTA Report.” 
indication and 
procedure 
all HTA reports and 
evidence used in HTAs 
 
8 reports 2007 - 2016 
Results 
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The artificial disc, which is the base for the procedure of a lumbar total disc 
replacement, received the CE-mark in 1987 or was at least marketed in Eu-
rope at this time. The CHARITÉ Artificial disc by DePuy Spine is the first 
disc to be reported about on the European market.141 142  
The first selected HTA in 2007 (HAS), 20 years after the CE-mark, was based 
on one systematic review, two randomized comparative prospective studies, 
seven prospective case-series, one retrospective case-series, seven case reports 
and three HTAs. The next HTA by LBI-HTA (2010) was based on twelve sys-
tematic reviews, eleven RCTs, one prospective cohort study and one non-com-
parative registry. The HTA conducted in 2014 (AETSA) included the evidence 
of seven randomized clinical trials, of which three were multicenter trials. 
The final selected HTA in 2015 (KCE) based their decision on one Cochrane 
review (including seven RCTs) and four additional RCTs. The weakest used 
evidence in the analyzed HTAs were case reports and case series (see Table 
4.2-10 below and Figure 8-5 in Appendix). 
The minimum level of evidence used in the analyzed HTAs was retrospec-
tive/prospective case-series, but mostly systematic reviews and RCTs were 
used, displaying a high level of evidence.  
Table 4.2-10: Summary of information of 4 HTA reports on lumbar total disc replacement 
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Lumbar 
total disc 
replacement 
Remplacement  
du disque 
interverte ́bral 
lombaire par 
prothe ̀se 
HAS 2007 1987 1 systematic review 
2 randomized comparative 
prospective studies 
7 prospective case series 
1 retrospective case series  
7 case reports 
3 HTAs 
http://bit.ly/29BPxa8 
Bandscheiben-
prothesen 
LBI-HTA 2010 12 systematic reviews 
11 RCTs  
1 prospective cohort study 
1 non-comparative registry 
http://bit.ly/29MdZbv 
Lumbar total  
disc replacement 
effectiveness and 
safety in chronic 
low back pain  
AETSA 2014 7 randomized clinical trials 
(3 multi center)  
http://bit.ly/29LO40w 
Cervical and 
lumbar total disc 
replacements  
KCE 2015 1 Cochrane review 
(including 7 RCTs) 
4 RCTs  
http://bit.ly/29tGA4l 
 
  
                                                             
141 The Medical Advisory Secretariat Ontario, “Artificial Discs for Lumbar and 
Cervical Degenerative Disc Disease –Update.” 
142 Geisler, “The CHARITE Artificial Disc.” 
detailed analysis  
of 4 HTAs: 
 
2007: 1 SR + 2RCT +  
7 case-series 
2010: 12SR + 11 RCT 
2014: 7 RCT 
2015: 1 SR of 7 RCT +  
4 RCT 
minimum: case-series, 
but mostly RCTs 
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4.2.6 Intraoperative radiation therapy (IORT) 
Intraoperative radiotherapy is a technology that delivers a (high) dose of ra-
diation therapy to the tumor bed during the surgery. The radiation does as 
little damage as possible to the surrounding tissue. This technology can re-
duce radiation treatment times or provide an added radiation boost. Because 
of fewer treatment sessions compared to standard radiation therapy and less 
exposure to healthy tissue, the therapy may reduce the side effects. The IORT 
differs to the standard radiation treatment in the range of irradiation. The 
standard treatment treats a whole area, while the IORT treats only the tissue 
surrounding the tumor. Currently, the IORT is used to treat breast and colo-
rectal cancer.143 
Table 4.2-11: Summary of institutes which conducted reports on IORT 
Institute Country Year of report Short form 
LBI-HTA Austria  2009 a 
KCE Belgium  2013  
AVALIA-T Spain  2013 b 
AVALIA-T Spain  2014 c 
HAS France  2016 d 
 
The IORT technology was assessed between 2009 and 2015 by four institutes 
through five HTA reports. Of those five, four (blue-colored rows) were select-
ed for an analysis of evidence used. The results are displayed in Table 4.2-11. 
In addition a short form (a, b, c, d) is assigned in order to locate the respective 
report in the evidence pyramid presented in the appendix (see Figure 8-6). 
The IORT was assessed by the AVALIA-T at two different points of time, con-
sidering in the first report breast cancer and in the second colorectal cancer. 
The first device CE-marked for that procedure was the INTRABEAM® Sys-
tem by Carl Zeiss Meditec in 1999.144 The IORT technology is comprising a 
multitude of different devices and different device generations, which can in-
fluence the available evidence.  
The first selected HTA in 2009 (LBI-HTA) – 10 years after CE-mark was based 
on one RCT, three non-randomized comparative studies, and 13 prospective 
uncontrolled studies. The following HTA in 2013 (AVALIA-T) concerning 
the treatment of breast cancer, was based on one meta-analysis, one system-
atic review, one RCT, nine comparative case series and 32 case series. The 
second HTA by AVALIA-T (2014) concerning colorectal cancer, includes two 
systematic reviews, three RCTs, one multi-national pooled analysis of case 
series and 17 case series. The final HTA by the French HAS in 2016 was based 
on two RCTs, two non-randomized controlled trials, two studies of unknown 
type, seven comparative retrospective studies, 15 uncontrolled prospective case-
series and three HTA reports.  
                                                             
143 “Cancer Treatment Centers of America (CTCA) | Intraoperative Radiation 
Therapy (IORT).” 
144 Market Wired, “Carl Zeiss Meditec | INTRABEAM Intraoperative  
Radiotherapy System.” 
indication and 
procedure 
all HTA reports and 
evidence used in HTAs 
 
5 reports: 2009-2015 
detailed analysis  
of 4 HTAs: 
 
2009: 3 CTs +  
13 case-series 
2013: 1 MA + SR +  
1 RCT + case-series 
2014: 2SR + 3RCT + 
case-series 
2016: 3 SR + 2RCT +  
2 CT + case-series 
Results 
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The minimum level of evidence used in the selected and analyzed HTAs were 
uncontrolled trials and case series (see Table 4.2-12 below and Figure 8-6 in 
Appendix). 
Table 4.2-12: Summary of information of 4 HTA reports on IORT 
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Intraoperative 
radiation 
therapy (IORT) 
Intraoperative 
Radiotherapie  
bei frühem 
Brustkrebs 
LBI-HTA 2009 1999 1 RCT  
3 non-randomized 
comparative studies 
13 prospective uncontrolled 
studies  
http://bit.ly/29BPZFn 
Intraoperative 
radiation therapy 
in the treatment of 
breast 
AVALIA-T 2013 1 meta-analysis  
1 systematic review  
1 RCT  
9 comparative case series  
32 case series  
http://bit.ly/1myxMpY 
Intraoperative 
radiation therapy 
in the treatment of 
colorectal cancer 
AVALIA-T 2014 2 systematic reviews  
3 RCTs  
1 multi-national pooled 
analysis of case series 
17 case series  
http://bit.ly/29DQQ9z 
Evaluation de  
la radiothe ́rapie 
perope ́ratoire dans 
le cancer du sein  
HAS 2016 2 RCTs  
2 non-randomized controlled 
trials  
2 other types of study 
7 comparative retrospective 
studies 
15 uncontrolled prospective 
case series 
3 HTAs 
http://bit.ly/29KMInU 
 
4.2.7 Sacral nerve stimulation (SNS) 
Sacral nerve stimulation is used as therapy for several indications. Here, the 
focus was on HTA assessments of sacral nerve stimulation for the treatment 
of fecal incontinence. Fecal incontinence occurs when a person is not able to 
control his/her bowel and cannot keep the feces in the rectum. This could re-
sult from a spinal injury, a dysfunction of the anal sphincter due to sphincter 
damage or a neurological disorder. For patients with a weak but intact sphinc-
ter, it is possible to adapt bowel and sphincter behavior by using the surround-
ing nerves and muscles. This procedure involves the stimulation of one of the 
sacral nerves by use of an electric current transmitted by an electrode through 
the associated sacral foramen. After a test trial phase of 2-3 weeks with a tem-
porary percutaneous peripheral nerve electrode, an implantable pulse gener-
ator can be implanted if the benefit of the procedure is considered signifi-
cant.145 
Between 2004 and 2016, eight HTA reports by seven institutes were conduct-
ed to assess the sacral nerve stimulation procedure. Of those eight reports, 
four were selected for an analysis of evidence used. The results are presented 
in Table 4.2-13. In addition a short form (a, b, c, d) is assigned in order to lo-
                                                             
145 “NICE | Sacral Nerve Stimulation for Faecal Incontinence.” 
minimum:  
retrospective case-series 
indication and 
procedure 
HTA reports and 
evidence used in HTAs 
 
8 reports 2004-2016 
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cate the respective report in the evidence pyramid presented in the appendix 
(see Figure 8-7). The first system used for this procedure, the InterStim® 
System by Medtronic, Inc., was CE-marked in 1994.146  
Table 4.2-13: Summary of institutes that conducted reports on SNS 
Institute Country Year of report Short form 
NICE England 2004 a 
Region Västra Götaland, HTA-Centrum Sweden  2009 b 
LBI-HTA Austria  2011 c 
HAS France 2013  
AQuAs Spain  2014 d 
VASPVT Lithuania 2014  
ZIN  Netherlands 2014  
NICE  England  2016  
 
The first report conducted in 2004 (NICE), 10 years after receiving the CE-
mark, was based on one unpublished prospective multicenter non-random-
ized trial, six case series and one double-blind crossover study; the HTA in 
2009 (The HTA Center of the Stockholm Country Council/Gotland) already 
included two RCTs. The HTA by the LBI-HTA in 2011 included one meta-
analysis, five systematic reviews, and one RCT. The final selected HTA by the 
Spanish AQuAS (2014) was based on one meta-analysis of different study de-
signs, one systematic review of RCTs, three studies with different study de-
signs, two RCTs, one quasi-experimental study and nine case series (see Ta-
ble 4.2-14 below and Figure 8-7 in Appendix). 
The initial level of evidence used in the HTAs was low-level case series but 
increased to high-level evidence studies such as RCTs, systematic reviews, and 
meta-analysis.  
Table 4.2-14: Summary of information of 4 HTA reports on SNS 
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Sacral nerve 
stimulation 
(SNS) 
Sacral nerve 
stimulation for the 
treatment of faecal 
incontinence 
NICE 2004 1994 1 unpublished 
prospective 
multicenter non-
randomized trial 
6 case series 
1 double-blind 
crossover study  
http://bit.ly/29MEiuy 
Sakralnervstimulering 
(SNS) vid fekal 
inkontinens  
The HTA Center 
of the Stockholm 
County Council/ 
Gotland 
2009 2 RCTs http://bit.ly/29xAH0S 
Sakralnervstimulation 
bei fäkaler 
Inkontinenz.  
Rapid Assessment  
LBI-HTA 2011 1 meta-analysis 
5 systematic 
review  
1 RCT 
http://bit.ly/2a8Hnc4 
                                                             
146 FDA, “InterStim | Summary of Safety and Effectiveness Data of Medtronic 
InterStim(R) System.” 
detailed analysis  
of 4 HTAs: 
 
2004: RCT + CT +  
6 case-series 
2009: 2 RCT 
2011: MA + 5 SR + RCT 
2014: MA + SR of RCT + 
2 RCT + case-series 
minimum:  
case-series 
Results 
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4.2.8 Robot-assisted surgery system 
Robotic surgery, computer-assisted surgery, and robotically-assisted surgery 
are terms for technological developments that use robotic systems to support 
surgical procedures. Instead of directly moving the instruments, the surgeon 
uses one of two tools to control the instruments: a direct telemanipulator or 
computer control. The surgeon controls the robotic arms via computer gadg-
etry and gets an inside view through a vision system, which delivers a 3-di-
mensional live picture. The robot, da Vinci®, can be used for cardiac, colorec-
tal, general, gynecologic, head and neck, thoracic and urologic surgeries.147, 148  
Table 4.2-15: Summary of institutes,  
which conducted reports on robot-assisted surgery systems 
Institute Country Year of report Short form 
AETSA Spain  2007  
AETSA Spain  2007  
AETSA Spain  2007  
AETSA Spain  2007  
ASSR Italy  2008 a 
KCE Belgium 2009 b 
UETS Spain  2011  
NIHR England  2012  
CEDIT France 2014 c 
LBI-HTA Austria  2015 d 
HAS France  2015  
 
Between 2007 and 2015, eight HTA institutes assessed the robot-assisted sur-
gery system technology in eleven reports. Of those eleven reports, four were 
selected For further analysis of evidence used. The results are presented in 
Table 4.2-15. In addition a short form (a, b, c, d) is assigned in order to locate 
the respective report in the evidence pyramid presented in the appendix (see 
Figure 8-8). The first robot-assisted surgery system that received the CE-mark 
in 1999 was the da Vinci® surgical system by Intuitive Surgical, Inc.149  
9 years after the CE-mark was granted, the first HTA selected for this study 
was conducted in 2008 (ASSR) and based on eight systematic reviews, five 
case series and four HTA reports by other institutes. The HTA in 2009 (KCE) 
was based on 18 HTAs, rapid assessments, systematic reviews or horizon scans 
and additional comparative studies and observational case series. In 2014, the 
French institute CEDIT conducted an HTA that included one systematic re-
view. The fourth selected report, conducted in 2015 (LBI-HTA, was based on 
two systematic reviews, eight RCTs, 14 non-randomized controlled trials and 
two HTA reports (see Table 4.2-16 below and Figure 8-8 in Appendix). 
                                                             
147 “LBI – HTA – Robotic-Assisted Surgery: A Systematic Review of Effectiveness 
and Safety for Elected Indications and Accumulating Costs.” 
148 “Da Vinci Surgery | Minimally Invasive Robotic Surgery with the Da Vinci 
Surgical System.” 
149 “Intuitive Surgical, Inc. | Da Vinci Surgical System.” 
Indication and 
procedure 
all HTA reports and 
evidence used in HTAs 
 
11 reports: 2007-2015 
detailed analysis  
of 4 HTAs: 
 
2008: 8 SR +  
5 case-series  
2009: 18 SR + CT +  
case-series 
2014: SR 
2015: 2 SR + 8 RCT + 14 CT 
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The weakest level of evidence were case-series and comparative trials, how-
ever, the majority of reports used systematic reviews and RCTs, resulting in 
an overall high level of clinical evidence.  
Table 4.2-16: Summary of information of 4 HTA reports on robot-assisted surgery systems  
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Robot-assisted 
surgery system 
La chirurgia 
robotica: il 
robot da Vinci 
ASSR 2008 1999 8 systematic reviews  
5 case series 
4 HTAs 
http://bit.ly/29F7vc4 
Robot-assisted 
surgery: health 
technology 
assessment  
KCE 2009 18 HTAs, rapid assessments, 
systematic reviews or 
horizon scans  
comparative studies 
observational case series  
http://bit.ly/29GiMsC 
Robotique 
chirurgicale en 
pe ́diatrie  
CEDIT 2014 1 systematic review http://bit.ly/29uJf9k 
Roboter-
assistierte 
Chirurgie 
LBI-HTA 2015 2 systematic reviews  
8 RCTs  
14 non-randomized 
controlled trials 
2 HTAs 
http://bit.ly/29Bd9cj 
 
4.2.9 Drug-eluting stents for  
peripheral artery diseases (DES) 
A stent is a small mesh tube used for the treatment of artery diseases. It is 
inserted into an artery to keep the artery lumen open. In order to place a 
stent patients undergo the procedure of a percutaneous coronary intervention 
(PCI), also known as a coronary angioplasty. The PCI renews the blood flow 
of blocked or narrow arteries and the stent helps to support the inner wall of 
the artery. One side effect of the procedure is the possibility of restenosis, in-
flammation, and fibrosis. In order to avoid this, drug-eluting stents are coat-
ed with a drug, to reduce inflammation and/or cell proliferation by releasing 
small therapeutic concentrations of the anti-inflammatory messenger mole-
cules in the surrounding tissue.150, 151 
Table 4.2-17: Summary of institutes which conducted reports on DES 
Institute Country Year of report Short form 
DIMDI Germany  2005  
UETS Spain  2006  
KCE Belgium  2007 a 
NICE England 2008 b 
HAS France  2009  
UETS Spain 2013  
UETS Spain  2013  
                                                             
150 “National Heart, Lung, and Blood Institute | What Is a Stent?” 
151 “NICE | Drug-Eluting Stents for the Treatment of Coronary Artery Disease.” 
minimum:  
case-series 
indication and 
procedure 
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Institute Country Year of report Short form 
LBI-HTA Austria  2014 c 
SBU Sweden  2014  
ASSR Italy 2014  
IQWIG Germany 2015  
Region Västra Götaland, 
HTA-Centrum 
Sweden 2015 d 
 
Between 2005 and 2015, twelve reports from ten HTA institutes assessed the 
drug-eluting stent technology. Four reports were selected for further pro-
cessing and to analyze the level of evidence used. The results are shown in 
Table 4.2-17. In addition a short form (a, b, c, d) is assigned in order to locate 
the respective report in the evidence pyramid presented in the appendix (see 
Figure 8-9). The first drug-eluting stent Cypher™ was CE-marked in 2002. 
The manufacturer Cordis Corporation used the drug Sirolimus to coat the 
stents.152  
The first HTA selected for this study was conducted in 2007 (KCE), 5 years 
after CE-mark, and was based on 29 meta-analyses, which consisted of 43 
RCTs. In 2008, NICE conducted an HTA (NICE) including one meta-analy-
sis, which was based on 17 RCTs. In 2014, (LBI-HTA) the HTA by an Aus-
trian institute was based on ten RCTs, five clinical controlled trials, and five 
case series. The fourth selected HTA by the Swedish HTA Center of the Stock-
holm County Council/Gotland (2015) was based on eleven systematic reviews 
or meta-analysis, 17 RCTs, four cohort studies and 13 case series (see Table 
4.2-18 below and Figure 8-9 in Appendix).  
The minimum level of evidence used in the analyzed HTAs were case series 
and cohort studies, however, the most evidence used were meta-analysis and 
systematic reviews, revealing a high level of clinical evidence at time of HTAs.  
Table 4.2-18: Summary of information of 4 HTA reports on DES  
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Drug-eluting 
stents for 
peripheral 
artery 
diseases 
Drug-eluting stents  
in Belgium: Health 
Technology Assessment 
KCE 2007 2002 29 meta-analyses 
(consisting out 
of 43 RCTs)  
http://bit.ly/29UaXRN 
Drug-eluting stents  
for the treatment of 
coronary artery disease 
NICE 2008 1 meta-analysis 
(consisting out 
of 17 RCTs)  
http://bit.ly/29SPngJ 
Medikamenten-
freisetzende Stents bei 
peripherer arterieller 
Verschlusskrankheit 
LBI-HTA 2014 10 RCTs  
5 Clinical 
controlled trials  
5 case series 
http://bit.ly/29SPbOC 
Drug eluting balloons 
and stents for 
symptomatic 
peripheral arterial 
disease  
The HTA Center 
of the 
Stockholm 
County Council/ 
Gotland 
2015 11 systematic 
reviews/meta-
analysis 
17 RCTs  
4 cohort studies  
13 case series  
http://bit.ly/29LNaRC 
 
                                                             
152 “Johnson & Johnson | Cordis’ CYPHER (TM) Sirolimus-Eluting Stent.” 
all HTA reports and 
evidence used in HTAs 
 
12 reports 2005-2015 
detailed analysis  
of 4 HTAs: 
 
2007: 29 MA of 43 RCT 
2008: 1MA of 17 RCT 
2014: 10 RCT + 5 CT +  
5 case-series 
2015: 11 SR + 17 RCT + 
case-series 
minimum: case-series, 
but mostly RCTs 
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4.2.10 Transcatheter aortic valve implantation 
(TAVI) 
Aortic stenosis is the narrowing of the aortic opening causing a restriction of 
the blood flow from the left ventricle of the heart to the aorta. As a result, 
the chronic compressive overload of the left ventricle leads to a left ventricle 
hypertrophy. Without treatment, this can cause cardiac insufficiency. A valve 
replacement usually requires open-heart surgery. Transcatheter aortic valve 
implantation (TAVI) is a minimal invasive treatment technique, and thus in-
dicated for patients whose conditions do not allow open-heart surgery. The 
procedure involves the implantation of an artificial valve onto the damaged 
valve without stopping the heart. Two options to implant the valve are pos-
sible: either transluminal, through a large artery such as the femoral or sub-
clavian artery or via a mini-thoracotomy with apical puncture of the left ven-
tricle, called the transapical approach.153, 154 
Table 4.2-19: Summary of institutes, which conducted reports on TAVI 
Institute Country Year of report Short form 
FinOHTA Finland 2008  
KCE Belgium  2008 a 
LBI-HTA Austria  2008 b 
HAS France  2008  
AGENAS Italy  2009  
LBI-HTA Austria 2009  
LBI-HTA Austria 2010  
LBI-HTA Austria 2011  
HIS Scotland  2011 c 
HIS Scotland 2011  
KCE Belgium  2011  
ASSR Italy 2012  
NICE England 2012 d 
HAS France  2013  
AVALIA-T Spain  2013  
NIHR England 2013  
HIS  Scotland 2014  
HIS Scotland 2014  
ZIN Netherlands 2014  
OSTEBA Spain  2014  
ASSR Italy 2014  
AVALIA-T Spain  2014  
 
                                                             
153 “NICE | Transcatheter Aortic Valve Implantation for Aortic Stenosis.” 
154 “KCE | Transcatheter Aortic Valve Implantation (TAVI): A Health Technology 
Assessment Update | HTA-Report.” 
indication and 
procedure 
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Between 2008 and 2014, twelve HTA institutes assessed TAVI through 22 re-
ports. Because of the importance of this advanced technology, several reports 
or updates were conducted. Of those 22 reports, four were selected for the 
analysis of the evidence level. The results are presented in Table 4.2-19. In ad-
dition a short form (a, b, c, d) is assigned in order to locate the respective re-
port in the evidence pyramid presented in the appendix (see Figure 8-10). 
Two manufacturers received the CE-mark for this technology in 2007 named 
Edwards Lifesciences with the balloon-expandable Edwards SAPIEN trans-
catheter heart valve and the self-expanding Medtronic CoreValve produced 
by Medtronic.155 
The first conducted HTA selected for this study in 2008 (KCE), 1 year after 
the CE-mark, was based on 12 case series, 13 single case reports, and five HTA 
reports. The update in 2011 included one RCT. The other HTA in 2008 (LBI-
HTA) was based on ten uncontrolled interventional studies. Updates were 
conducted in 2009 and 2010 and the evidence used was based on four uncon-
trolled before-after studies (2009) and five uncontrolled before-after studies, 
respectively, and additionally four HTAs in 2010. The 2011 update included 
one RCT, nine uncontrolled studies, six registry studies and 18 background 
studies. The report in 2011 (HIS) was based on three systematic reviews, one 
RCT and five HTA reports by other institutes. The update in 2014 included 
one RCT. The final selected HTA in 2012 (NICE) was conducted on the base 
of one systematic review, two RCTs, one non-randomized comparative study 
and six case series (see Table 4.2-20 below and Figure 8-10 in Appendix).  
The weakest evidence used in the analyzed HTAs were case reports and case 
series, revealing a low level of clinical evidence at time of HTAs. However, 
later HTA reports (2011) were based on RCTs and systematic reviews, which 
reflect a high level of clinical evidence.  
  
                                                             
155 Phang, Tay, and Hon, “Transcatheter Aortic Valve Implantation-2014 Update.” 
all HTA reports and 
evidence used in HTAs 
 
22 reports: 2008-2014 
detailed analysis  
of 4 HTAs: 
 
2008: 5 SR + 12 case-
series + 13 case-reports 
2008: 10 case-series 
2011: 8SR + 1RCT 
2012: 1SR + 2RCT +  
case-series 
minimum:  
case reports 
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Table 4.2-20: Summary of information of 4 HTA reports on TAVI 
Technology HTA title Institute 
Year of 
report 
Year of 
CE-mark Evidence Link 
Transcatheter 
Aortic Valve 
Implantation 
(TAVI) 
Percutaneous heart 
valve implantation  
in congenital and 
degenerative valve 
disease 
Transcatheter Aortic 
Valve Implantation 
(TAVI) 
KCE 2008 
2011 
2007 2008 
12 case series 
13 single case reports 
5 HTAs  
2011 
1 RCT 
http://bit.ly/29xyiDL 
http://bit.ly/29ATCKD 
Minimal-invasiver 
perkutaner Aorten-
klappenersatz 
(2008/2009/2010)  
Minimal-invasiver 
perkutaner Aorten-
klappenersatz/TAVI 
(2011) 
LBI-HTA 2008 
2009 
2010 
2011 
2008/2009/2010 
10 uncontrolled 
interventional studies 
+ 4 uncontrolled 
before-after studies 
+ 5 uncontrolled 
before-after studies 
4 HTAs 
2011 
1 RCT 
9 uncontrolled studies 
6 registry studies 
18 background studies 
http://bit.ly/29LMXxP 
http://bit.ly/29JzsQr 
http://bit.ly/29KrhVJ 
http://bit.ly/29ESJ6f 
Transcatheter aortic 
valve implantation 
(TAVI) for severe 
symptomatic aortic 
stenosis in adults 
Note 33/38 
Transcatheter aortic 
valve implantation 
(TAVI for severe 
symptomatic aortic 
stenosis in adults at 
high surgical risk/in 
adults who are not 
eligible for surgery 
Note 51/52 
HIS 2011 
2014 
 
   2011 
3 systematic reviews 
1 RCT 
5 HTAs  
2014  
1 RCT 
http://bit.ly/29LMw6O 
http://bit.ly/29Jyvb2 
http://bit.ly/29ATJpt 
http://bit.ly/29Kq40A 
Transcatheter aortic 
valve implantation for 
aortic stenosis 
NICE 2012 1 systematic review 
2 RCTs  
1 non-randomized 
comparative study 
6 case series 
http://bit.ly/29A1pwd 
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5 Discussion 
This research had two main objectives:  
 to identify the critical points in the assessment of medical devices 
discussed in the recent literature.  
 to analyze the timing of the HTA reports of European HTA institutes 
in relation to the year of CE-mark and the level of evidence used in the 
HTAs.  
 
 
5.1 Summary: Literature Review  
A systematic literature review analyzing published literature from 2010 un-
til 2016 brought insights into the critical points of the assessment of medical 
devices. Table 5.1-1 gives an overview of the results found and the conclu-
sions made.  
Table 5.1-1: Critical points in the assessment of medical devices and procedures discussed in publications 
Missing of robust  
evidence 
 Weak clinical evidence is required for receiving the CE-mark, not suitable to meet the 
evidence-requirements of European HTA institutes to support reimbursement decisions.  
Methodology 
applied 
 No specific methods for the different kinds of high-risk medical devices  
(diagnostic and therapeutic) exist. 
 The Influence of specific aspects of medical devices such as the learning curve of 
operators and the incremental innovation is not reflected in HTA methodology. 
Harmonization of 
HTA requirements  
 Different requirements, if any, exist for the minimal evidence used in the HTA reports. 
 The harmonization of requirements might be a driver for reducing redundancy of 
assessing the same technology or procedure multiple times.  
Impact on 
decisions  
 The impact of the HTAs of medical devices on decision-making in different 
institutions is not well known. 
Timing of 
assessment 
 Due to lack of a clearly defined market entry of medical devices, difficulties in 
conducting the assessment at the right time in the products life cycle exist. 
 
The presented critical points and challenges in the assessment of medical 
devices differ from issues discussed on pharmaceuticals. Each of the criti-
cal points can be related to the unique characteristics of medical devices and 
their market authorization. Additionally, some of these points are interrelat-
ed such as the harmonization and methodology in HTA of medical devices.  
The critical points vary in their importance or influence on the assessment 
of medical devices. The challenge of receiving robust clinical data is the most 
discussed critical point in recent publications: several severe (late) adverse 
events (e.g. with breast implants or metal-on-metal hip implants) have led to 
a dispute about the submitted clinical evidence in the regulatory approval pro-
cess and the need for post-marketing surveillance. Therefore, the new EU di-
rective aims at modernizing the current legislations for the regulation of med-
ical devices by strengthening the rules for placing medical devices on the mar-
ket as well as the post-market surveillance. 
2 research objectives: 
- identify critical issues 
discussed  
- characteristics of 
European HTA on 
medical devices 
critical issues discussed 
in recent publications 
issues discussed differ 
from pharma 
related to market 
authorization and 
methodology 
vary in importance  
or influence  
 
most important:  
robust evidence for 
approval 
post-market surveillance 
data for safety 
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Several studies and reviews criticize the considerably large differences be-
tween the methodological standards for pharmaceuticals and medical devic-
es, in the sense that pharmaceutical methodology is further developed than it 
is for medical devices. In contrast to pharmaceuticals, the discussion on evi-
dence requirements for medical device assessments is relatively new and needs 
time to develop extensive and specific methods suiting their unique charac-
teristics. 
 
 
5.2 Summary: Redundancies 
Multiple HTA reports on the same technology or procedure are conducted 
either within the same year or over several years. A data analysis of all – in 
2014 – identified HTA reports on medical devices risk-class 2b and 3 (see 
Table 8-1 in Appendix) and of ten selected technologies and procedures (see 
Table 8-2 in Appendix) revealed the amount of the redundancies:  
Figure 5.2-1 and Figure 5.2-2 present the reports that were conducted over 
time. The number of reports per technology or procedure range between five 
for IORT and 22 for TAVI: 
 5 HTA-reports on IORT (2013: 2 times) 
 8 HTA-reports on lumbar total disc replacement (2015: 2 times) 
 8 HTA-reports on SNS (2014: 3 times) 
 9 HTA-reports on Mitraclip® (2012: 3 times) 
 11 HTA-reports on IMRT (2010: 3 times) 
 11 HTA-reports on CRT-P, CRT-D (2014: 4 times) 
 11 HTA-reports on robot-assisted surgery (2007: 4 times) 
 12 HTA-reports on DES (2014: 3 times) 
 12 HTA-reports on HIFU (2010: 4 times)  
 22 HTA-reports on TAVI (2008: 4 times; 2011: 4 times; 2014: 6 times) 
The lowest number of reports conducted in a year for a technology is one re-
port, while the highest number is six reports in one and the same year.  
It is obvious that there is a huge potential for collaboration: be it building on 
each other´s HTA in successive years or collaborating within the same year. 
These data show the importance of European collaboration in HTA. As dis-
cussed in recent publications the redundancy of HTA-reports leads to waste 
in human and financial resources.156  
                                                             
156 Mathes et al., “Methods of International Health Technology Assessment Agencies 
for Economic Evaluations-a Comparative Analysis.” 
pharma:  
advanced methods 
available 
not so for medical 
devices  
high redundancy 
for 10 selected 
technologies 
 
range 5-22 HTAs 
 
1-6 for same tech p.a. 
huge potential for 
collaboration  
Discussion 
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Figure 5.2-1: Comparison of reports conducted on the same technology (1-5) 
 
Figure 5.2-2: Comparison of reports conducted on the same technology (6-10) 
Not only methodology but language seems to be the major barrier for collab-
oration: In the European Union currently 24 different official languages are 
spoken.157 The reports used for this research were conducted in seven differ-
ent languages (English, French, Spanish, Italian, German, Polish and Swe-
dish). Therefore, an increasing harmonization in the use of a common lan-
guage should be considered.  
                                                             
157 “EUROPA – EU Administration – Staff, Languages and Location.” 
EU:  
24 official languages 
reports analyzed: 
7 languages 
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5.3 Summary: Level of Evidence used 
As seen in Table 5.3-1, there is a – natural – trend regarding the evidence used: 
the best available evidence is being used at time (year) of assessment (see al-
so evidence pyramids in Appendix Figures 8-1 to 8-10). In general, the first 
reports (early assessment) are based on rather low clinical evidence (case re-
ports and retrospective case-series), while the latter reports are conducted on 
somewhat stronger clinical evidence (prospective case-series, non-randomized 
comparative trials, and randomized clinical trials), sometimes for one indi-
cation only, but also for several indications. The use of systematic reviews (SR) 
in the evidence pyramid is somewhat misleading, since SR can be based on 
RCTs, but also on less robust study designs (case-series). 
In the selected 10 technologies and four analyzed HTA-reports no trend could 
be identified concerning not using very low clinical evidence (case reports or 
retrospective case-series) at all for assessing technologies. This study did not 
analyses, however, if the HTA-requirements became more rigorous in recent 
years. 
Table 5.3-1: Summary of findings in the comparison of HTA institutes 
Device or procedure Institute Report year Level of used evidence Year of CE-mark 
Implantable cardiac 
resynchronization therapy 
and defibrillator  
(CRT-D/CRT-P) 
SBU 
AETSA 
AGENAS 
Swiss Medical Board 
2003 
2009 
2014 
2015 
Level 3 
Level 1 
Level 1 
Level 1 
2001 
MitraClip®  LBI-HTA 
Stockholm County Council 
HTA-Center OSTEBA 
HAS 
2010 
2012 
 
2014 
2015 
Level 4 
Level 3 
 
Level 2 
Level 3 
2008 
Intensity-modulated 
radiation therapy (IMRT)  
AVALIA-T 
KCE 
NIHR 
OSTEBA 
2005 
2007 
2010 
2014 
Level 7 
Level 3 
Level 2 
Level 5 
- 
High intensity focused 
ultrasound (HIFU)  
NICE 
LBI-HTA 
AGENAS 
AOTMIT 
2005 
2010 
2011 
2014 
Level 7 
Level 7 
Level 5 
Level 2 
1999/2000 
Lumbar total disc 
replacement 
HAS 
LBI-HTA 
AETSA 
KCE 
2007 
2010 
2014 
2015 
Level 2 
Level 2 
Level 3 
Level 2 
1987 
Intraoperative radiation 
therapy (IORT) 
LBI-HTA 
AVALIA-T 
AVALIA-T 
HAS 
2009 
2013 
2014 
2016 
Level 3 
Level 1 
Level 2 
Level 3 
1999 
Sacral nerve stimulation 
(SNS) for fecal incontinence 
NICE 
HTA Center of 
Stockholm/Gotland  
LBI-HTA 
AQuAs 
2004 
2009 
 
2011 
2014 
Level 4 
Level 3 
 
Level 1 
Level 1 
1994 
clinical evidence is  
 – naturally –  
evolving over time 
 
later assessments: 
better evidence 
no trend for  
„lower limit” identified 
Discussion 
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Device or procedure Institute Report year Level of used evidence Year of CE-mark 
Robot-assisted surgery 
systems  
ASSR 
KCE 
CEDIT 
LBI-HTA 
2008 
2009 
2014 
2015 
Level 2 
Level 2 
Level 2 
Level 2 
1999 
Drug-eluting stents (DES) 
for peripheral artery disease 
(PAD) 
KCE 
NICE 
LBI-HTA 
HTA Center of 
Stockholm/Gotland 
2007 
2008 
2014 
2015 
Level 1 
Level 1 
Level 3 
Level 1 
2002 
Transcatheter aortic valve 
implantation (TAVI)  
KCE 
LBI-HTA 
HIS 
NICE 
2008 
2008 
2011 
2012 
Level 7 
Level 4 
Level 3 
Level 2 
2007 
 
 
5.4 Summary:  
Timing and Clusters of Institutes 
For a comprehensive grouping of HTA-institutes based on timing of their as-
sessments to potentially distinguish between early and late assessors not on-
ly the four selected and analyzed HTA reports, but all HTA reports for the 
ten technologies were used for the clustering analysis. The data are displayed 
in Figure 5.4-1. The institutes were summarized to their country of origin 
(n = 14), because of the high number of different institutes (n = 27) in order 
to reduce complexity. The bubbles mark each of the reports (n = 109).  
The countries with the most published reports are Spain (25), England (14), 
Austria and France (13), Belgium (10) and Italy (9), some of them are updates 
of earlier reports. For the clustering of the institutes, we intended to build 
groups of HTA-institutes according to their timing in relation to the other 
European assessments. E.g. for three technology-assessments (IMRT, HIFU, 
SNS) England was the first assessor in Europe, but for other technologies 
(total disc replacement, TAVI, robot-assisted surgery) it was later. 
The data can also be presented taking a different perspective: Figure 5.4-2 
shows which of the 10 selected technologies was assessed at which point in 
time in relation (proximity) to the market authorization (CE-mark) from which 
countries.  
Table 5.4-1 presents the countries and agencies that were engaged in assessing 
the 10 selected technologies. 
To summarize the clustering exercise: there is no clear picture that allows con-
cluding on early or late assessors (Figure 5.4-1). Nevertheless, it shows that 
some countries (and agencies) have assessed almost all selected technologies 
(Figure 5.4-2 and Table 5.4-1) and some of them have assessed the technolo-
gies even several times along the evolvement of evidence and along the life-
cycle, updating earlier assessments. Additional there is considerably in-coun-
try redundancy (esp. in Spain). 
These countries and agencies (Table 5.4-1) might be the candidates for col-
laborating in future European joint assessments. 
 
clustering for timing  
of 109 assessments 
of 10 technologies  
and 14 countries  
most reports on  
medical devices: 
 
Spain, England, Austria, 
France, Belgium, Italy 
no cluster of early/late 
assessors identifiable 
countries and agencies: 
candidates for 
collaborating  
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Figure 5.4-1: HTA reports performed for the ten interventions 
 
Figure 5.4-2: Distribution of CE-mark to the used HTA reports  
  
Discussion 
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Table 5.4-1: 10 selected technologies: Countries and HTA agencies that conducted assessments 
Country Agencies Technologies  
Spain AETSA:  
UETS 
OSTEBA 
AVALIA-T 
AQuAS  
CRT, IMRT, HIFU, disc replacement, robot surgery 
CRT, HIFU, robot surgery, DES 
Mitraclip, IMRT, TAVI 
IMRT, IORT, TAVI 
HIFU, SNS 
Austria LBI-HTA  Mitraclip, HIFU, disc replacement, IORT, SNS, robot surgery, DES, TAVI 
France CEDIT  
HAS  
Mitraclip, robot surgery 
Mitraclip, IMRT, HIFU, disc, IORT, SNS, robot surgery, DES, TAVI 
England NIHR 
NICE  
CRT, IMRT, HIFU, robot surgery, TAVI 
CRT, HIFU, disc replacement, SNS, DES, TAVI 
Italy AGENAS 
ASSR 
CRT, HIFU, disc replacement, TAVI 
IMRT, robot surgery, DES, TAVI 
Belgium KCE CRT, IMRT, disc replacement, IORT, robot surgery, DES, TAVI) 
Sweden SBU 
St. County Council 
Metodra ̊det i Sydo ̈stra 
Sjukva ̊rdsregionen  
Västra Götalandsregionen 
CRT, DES 
Mitraclip 
disc replacement 
 
SNS, DES 
Switzerland Swiss Medical Board CRT, disc replacement disc 
Scotland HIS CRT, Mitra, TAVI 
Poland AOTMIT  Mitraclip, HIFU 
Germany IQWIG 
DIMDI 
HIFU, DES 
DES 
Netherlands ZIN HIFU, SNS, TAVI 
Lithuania VASPVT  SNS 
Finland FinOHTA TAVI 
 
 
5.5 Limitations of this research 
This study has several limitations that have to be recognized. Only literature 
from 2010 until 2016 was reviewed to obtain the recently discussed critical 
points. 
For the data analysis, only European HTA institutes, agencies ad units were 
included, due to the shared regulatory framework. Other jurisdictions like 
United States, Canada or Australia were excluded.  
The focus was limited to high-risk medical devices (risk-class 2b and 3 and 
active implantable devices) because these are the ones attracting most inter-
est from the European HTA institutes. Of these high-risk devices, the 10 most 
frequently assessed technologies were selected for further investigation and 
limited to detailed analysis of four 4 reports only. The 10 different technolo-
gies chosen for this study represent only a small percentage of all devices on 
the European market.  
Any generalization must be considered in the context of these limitations. 
Additionally, the HTA reports had to have a clear statement of the evidence 
used. The information on the year of the market authorization (CE-mark) is 
based on company announcements, investor reports and news articles on mar-
keted products only. Hence, it is probable that some of the identified CE-
mark dates vary, due to lack of official published sources.  
Additionally, only publicly accessible information was included.  
only literature from 
2010 till 2016 
only European  
HTA report included 
only high-risk  
medical devices  
limited scope for 
analysis 
cautious generalization  
only publicly accessible 
information used 
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6 Conclusion 
This research project aimed at contributing to the efforts of increasing  
European collaboration on HTA of medical devices.  
It can be concluded that  
 even if it cannot be foreseen in detail if and how the new regulation 
of medical devices in Europe will change the clinical evidence required 
at time of market authorization (CE-marking), 
 the collaboration between European HTA-institutions is occurring 
more frequently, supported by the European Commission and facili-
tated within the structures of EUnetHTA Joint Action 3 and the vari-
ous tools developed to support such collaborations. 
 Within this collaboration, a harmonization of methodologies (guide-
lines), of formats (Core Model® and manufacturer submission template) 
and even of language (English as working language) is evolving. 
 The data analysis of timing of the diverse assessments of medical de-
vices showed clearly that only some assessments of similar products are 
conducted within the same year, but most often within a time-range of 
several (even more than 10) years. 
 The analysis of the HTA reports indicates that there is room for im-
provement regarding the collaboration of HTA institutes in Europe, 
since many reports were redundant or overlapping. One possible way 
to use resources more efficiently could be clustering of HTA institutes 
with similar work profiles.  
 
contribution of  
this research: 
 
systematic data analysis  
 
of redundancies of  
HTA products 
 
and 
 
of clusters of European 
HTA agencies with a 
similar profile 
 
collaboration! 
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Table 8-1: All HTA reports (high risk medical devices risk class 2b, 3 and active implantable) conducted in 2014 (n = 87) 
Institute 
Taxonomic 
position Technology(ies) Full title of report 
AAZ 27 Triclosan-coated sutures Impact of triclosan-coated sutures on surgical site infection 
AETSA 9 Digital tomosynthesis  Digital tomosynthesis in breast cancer 
AETSA 26 Interspinous decompression devices  Effectiveness and safety of interspinous devices.  
AETSA 29 Lumbar total disc replacement  Lumbar total disc replacement effectiveness and safety in chronic low back pain. 
Agenas 27 Ultrasonic devices  Rapid HTA report: Ultrasonic energy devices for surgery 
Agenas 14, 32 ICD Rapid HTA report. Implantable cardiac resynchronization therapy and 
defibrillator (CRT-D) in patient with heart failure 
AOTMiT 27 HIFU Leczenie raka stercza skupioną wiązką ultradźwiękową  
ASSR 4, 25, 25, 4 Sensor Augmented Pump (SAP); Continuous subcutaneous insulin 
infusion (CSII); Continous blood monitoring systems devices (CGMS) 
Dispositivi medici innovativi nella gestione del diabete  
AVALIA-T 26 Repair mesh Mallas transvaginales en la reparación del prolapso de órganos pélvicos  
AVALIA-T 27 IORT Radioterapia intraoperatoria en el tratamiento del cáncer colorrectal  
AVALIA-T 27 Photopheresis  Fotoaféresis para pacientes con enfermedad de injerto contra huésped 
resistente a esteroides. 
AVALIA-T 27 Brachytherapy Braquiterapia de alta tasa en el tratamiento de tumores de lengua móvil  
AVALIA-T 27 Ablation (Pancratic and hepatic cancer) Efectividad y seguridad de la electroporación irreversible en el tratamiento de 
los cánceres de páncreas e hígado  
AVALIA-T 30 Stents retrievers Seguridad y eficacia de la trombectomía mecánica mediante stents retrievers 
en el tratamiento del ictus isquémico agudo  
CAHIAQ (AQuAs) 27 Proton therapy La protonterapia en el tratamiento del cáncer  
CAHIAQ (AQuAs) 32 Sacral nerve stimulation (SNS) La estimulación deraíces sacras para el tratamiento dela incontinencia fecal: 
revisión de la eficacia y análisis de coste-efectividad 
CEDIT 27 DaVinci Robotic Surgery  Intérêt de la robotique chirurgicale da Vinci en pédiatrie 
CVZ (ZiN) 26 Duodenal-Jejunal bypass (EndoBarrier) Duodenal-Jejunal bypass (EndoBarrier) voor de behandeling van obesitas met 
of zonder Diabetes Mellitus type II  
CVZ (ZiN) 27 sleeve gastrectomy Standpunt Bariatrische Chirurgie• sleeve bij gastrectomie• bij DM2 én BMI 
tussen 30 en 35  
CVZ (ZiN) 27 Extracorporeal Shock Wave Therapy Extracorporeal Shock Wave Therapy bij Achillespees Tendinopathie  
CVZ (ZiN) 29 Transcatheter aortic valve implantation (TAVI) Transcatheter aortic valve implantation (TAVI) 
CVZ (ZiN) 30 Trans-Arterial chemoembolisatie (TACE) Transarteriële Chemoembolisatie (TACE) bij Neuroendocriene 
Levermetastasen (NELM)  
CVZ (ZiN) 30 Trans-Arterial chemoembolisatie (TACE) and/or laser-induced 
thermotherapy (LITT) 
Transarteriële chemoembolisatie (TACE) en/of laser geïnduceerde 
thermotherapie (LITT) bij colorectale levermetastasen  
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Institute 
Taxonomic 
position Technology(ies) Full title of report 
CVZ (ZiN) 30 Trans-arterial chemo-embolization (TACE) Transarteriële chemo-embolisatie (TACE) bij levermetastasen van 
pancreascarcinoom  
CVZ (ZiN) 30 Minimally invasive lumbar interbody fusion Standpunt Minimaal invasieve lumbale interbody fusie  
CVZ (ZiN) 32 Sacral neurostimulation Sacrale neurostimulatie bij kinderen en volwassenen met  
therapieresistente functionele obstipatie  
FinOHTA 30 Sutureless aortic valve replacement Sutureless valve replacement for aortic valve stenosis 
HAS 9 EBUS-TBNA Endobronchial ultrasound-guided transbronchial needle aspiration  
HAS 29 Shoulder joint implant Assessment of shoulder joint implants 
HAS 29 Hip implants Hip implants 
HAS 30 Ultrasound guidance for PNB Ultrasound guidance for peripheral nerve blockade 
HAS 32 Spinal cord stimulation (neurostimulators) Assessment of spinal cord stimulation 
HVB 27 Radiofrequency ablation Radiofrequenzablation bei benignen und malignen Veränderungen der 
Schilddrüse. Update 
IQWiG 29 Stents Stents zur Behandlung intrakranieller arterieller Stenosen  
KCE 27 Machine perfusion Machine perfusion in kidneys from decreased donoers- a rapid assessment  
KCE 26, 27 intraocular lenses; laser refractive surgery Correction of refractive errors of the eye in adults- part 2: Laser surgery and 
intraocular lenses) 
LBI 26 endobronchial valve implantation Endobronchiale Ventilimplantation bei Lungenemphysem. Systematischer 
Review – 3. Update 2014. Decision Support Dokument Nr. 20/Update 2014 
LBI 27 Stereotactic Radio 
Frequency Ablation 
Stereotaktische Radiofrequenztherapie/SRFA bei Leberzellkarzinom und 
Lebermetastasen. Systematischer Review 
LBI 27 Cytoreduction surgery (CRS) combined with intraoperative, intra-
peritoneal, hyperthermic chemotherapy (HIPEC/HIIC/IPCH/IPHC) 
Zytoreduktive Chirurgie und hypertherme intraperitoneale Chemotherapie 
bei Peritonealkarzinose. Systematischer Review 
LBI 29 drug-eluting stent Medikamentenfreisetzende Stents bei peripherer arterieller 
Verschlusskrankheit. Systematischer Review 
LBI 30 Percutaneous (transcatheter transseptal) Left Atrial Appendage 
Occlusion/Obliteration/Exclusion (different devices p10) 
Perkutaner Verschluss des linken Vorhofohres zur Thrombembolieprophylaxe 
bei PatientInnen mit Vorhofflimmern. Systematischer Review. 1. Update 2014 
NICE 29 Protheses Total hip replacement and resurfacing arthroplasty for endstage arthritis of 
the hip (review of technology appraisal guidance 2 and 44) (TA304) 
NICE 29 MAGEC (spinal implants (growing rods) and an External Remote 
Controller) 
The MAGEC system for spinal lengthening in children with scoliosis (MTG18) 
NICE 30 ReCell Spray-On Skin system The ReCell Spray-On Skin system for treating skin loss, scarring and 
depigmentation after burn injury 
NICE medical technology guidance [MTG21] 
NICE 32 implantable defibrillator Implantable cardioverter defibrillators and cardiac resynchronisation therapy 
for arrhythmias and heart failure (review of TA95 and TA120) (TA314) 
NICE 12 Optical Coherence Tomography (using catheter) Optical coherence tomography to guide percutaneous coronary intervention 
(IPG481) 
NICE 26 Jaw Replacement Total prosthetic replacement of the temporomandibular joint (IPG500) 
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Institute 
Taxonomic 
position Technology(ies) Full title of report 
NICE 26 Magnetic Bead Band Insertion of a magnetic bead band for faecal incontinence (IPG483) 
NICE 27 Radiofrequency Ablation Endoscopic radiofrequency ablation for squamous dysplasia of the 
oesophagus (IPG497) 
NICE 27 Radiofrequency Ablation Endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade 
dysplasia or no dysplasia (IPG496) 
NICE 27 Laser Surgery Transoral carbon dioxide laser surgery for primary treatment of 
oropharyngeal malignancy (IPG484) 
NICE 27 Prostatic urethral lift implants Insertion of prostatic urethral lift implants to treat lower urinary tract 
symptoms secondary to benign prostatic hyperplasia 
NICE interventional procedure guidance [IPG475] 
NICE 27 Chemosaturation Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein 
isolation for primary or metastatic liver cancer (IPG488) 
NICE 27 Radiofrequency Turbinoplasty Radiofrequency tissue reduction for turbinate hypertrophy (IPG495) 
NICE 27 Radiofrequency Ablation Radiofrequency ablation of the soft palate for snoring (IPG476) 
NICE 27 Athroscopic radiofrequency chondroplasty Arthroscopic radiofrequency chondroplasty for discrete chondral defects of 
the knee (IPG493) 
NICE 29 Gastroelectrical Stimulation Gastroelectrical stimulation for gastroparesis (IPG489) 
NICE 29 Transcatheter Aortic Valce Replacement Transcatheter valve-in-valve implantation for aortic bioprosthetic valve 
dysfunction (IPG504) 
NICE 29 Stent Bioresorbable stent implantation for treating coronary artery disease (IPG492) 
NICE 29 Collagen Plug Insertion of a collagen plug to close an abdominal wall enterocutaneous 
fistula (IPG507) 
NICE 30 Extracorporeal Membrane Oxygenation Extracorporeal membrane oxygenation (ECMO) for acute heart failure in 
adults (IPG482) 
NICE 30 Insertion of an annular disc implant Insertion of an annular disc implant at lumbar discectomy 
NICE interventional procedure guidance [IPG506] 
NICE 32 Adjustable Pulmonary Artery Banding Telemetric adjustable pulmonary artery banding for pulmonary hypertension 
in infants with congenital heart defects (IPG505) 
NICE 32 Battery-Powered Drainage System Subcutaneous implantation of a battery-powered catheter drainage system 
for managing refractory and recurrent ascites (IPG479) 
NIHR 30 Fenestrated and branched endovascular aneurysm repair  The use of fenestrated and branched endovascular aneurysm repair for 
juxtarenal and thoracoabdominal aneurysms: a systematic review and  
cost-effectiveness analysis  
NIHR 30 Percutaneous vertebroplasty (PVP) vs. Percutaneous balloon 
kyphoplasty (BKP) 
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the 
treatment of osteoporotic vertebral fractures: a systematic review and cost-
effectiveness analysis 
NIHR 30 percutaneous transluminal balloon angioplasty Enhancements to angioplasty for peripheral arterial occlusive disease: systematic 
review, cost-effectiveness assessment and expected value of information analysis 
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Institute 
Taxonomic 
position Technology(ies) Full title of report 
NIHR 6, 9 magnetic resonance diffusion-weighted brain imaging vs. 
computed tomography (CT) brain scanning 
An assessment of the cost-effectiveness of magnetic resonance, including 
diffusion-weighted imaging, in patients with transient ischaemic attack and 
minor stroke: a systematic review, meta-analysis and economic evaluation 
OSTEBA 27 IMRT An evaluation of intensity-modulated radiotherapy (IMRT) 
OSTEBA 27 IMRT New IMRT techniques for moving targets. An analysis of their safety and efficacy. 
OSTEBA 29 MitraClip® MitraClip® para la reparación del reflujo de la válvula mitral 
OSTEBA 29 Bioresorbable peripheral stents Stents periféricos biorreabsorbibles.  
OSTEBA 29 Percutaneous aortic valve replacement using prosthetic valve 
versus the standard surgical treatment 
Análisis coste-efectividad del recambio valvular aórtico mediante prótesis 
valvular percutánea frente al tratamiento quirúrgico habitual. 
OSTEBA 30 Cryoablation with Arctic Front catheter Crio-ablación en la fibrilación auricular con catéter Arctic-Front. 
OSTEBA 32 Magnetic resonance compatible pacemaker Marcapasos Compatible con Resonancia Magnética.  
OSTEBA 32 Subcutaneous defibrillator Desfibrilador subcutáneo. 
Regione Veneto  27 Renal denervation system  DENERVAZIONE RENALE 
Regione Veneto  29 Sutureless aortic valves (Perceval S Tm, 3f Enable® (Modello 6000), 
Edwards INTUITY Elite Valve System) 
PROTESI VALVOLARE AORTICA A RILASCIO CHIRUGICO VELOCE: 
RIVALUTAZIONE 
Regione Veneto  30 Transcatheter ablation  TRATTAMENTO NON FARMACOLOGICO DELLA FIBRILLAZIONE ATRIALE: 
ABLAZIONE TRANSCATETERE E ABLAZIONE CHIRURGICA 
SBU 27 Low Level Laser Therapy Laser treatment of neck pain 
SBU 29 drug-eluting stents Drug-eluting stents in coronary arteries 
SBU 6, 9 MRI; PET/CT; doppler ultrasound; applications of ultrasound 
techniques such as elastog raphy; HistoScanning® 
Diagnostic Imaging in Suspected Prostate Cancer 
SHTG/HIS 27 renal denervation (RDN) Evidence note 54: What is the clinical effectiveness, cost effectiveness and 
safety of treatment with renal denervation (RDN) for patients with resistant 
hypertension (RH), and what model of treatment centres should be adopted?  
Advice Statement 004/14: Renal denervation for patients with resistant 
hypertension 
SHTG/HIS 29 TAVI Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic 
stenosis in adults who are not eligible for surgery: Evidence note 51.  
Advice Statement 001/14 
Is Transcatheter aortic valve implantation (TAVI) clinically and cost effective for 
severe symptomatic aortic stenosis in adults who are not eligible for surgery? 
SHTG/HIS 29 TAVI Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic 
stenosis in adults at high surgical risk: Evidence note 52. Advice Statement 
002/14. Is Transcatheter aortic valve implantation (TAVI) clinically and cost 
effective for severe symptomatic aortic stenosis in adults at high surgical risk? 
UETS 27 Brachytherapy and external beam radiation  Efectividad comparada del tratamiento conservador del cáncer de mama con 
braquiterapia y radioterapia externa  
UETS 30 hip resurfacing and traditional total hip arthroplasty Eficacia y seguridad de la prótesis de cadera de superficie frente a la 
artroplastia convencional  
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Table 8-2: All HTA reports on 10 selected technologies (n = 109) 
Technology HTA title Institute Year Link-shortened 
Transcatheter Aortic Valve 
Implantation (TAVI) 
Transcatheter aortic valve replacement for severe aortic valve stenosis FinOHTA 2008 http://bit.ly/29LMqfd 
  Minimal-invasiver perkutaner Aortenklappenersatz LBI-HTA 2008 http://bit.ly/29LMXxP 
  Percutaneous heart valve implantation in congential and degenerative valve disease.  
A rapid Health Technology Assessment 
KCE 2008 http://bit.ly/29xyiDL 
  Évaluation des bioprothe ̀ses valvulaires aortiques implante ́es par voie re ́trograde 
transfe ́morale et transapicale  
HAS 2008 http://bit.ly/29A85VT 
  TransApical Transcatheter Aortic Valve Implantation (TA-TAVI) AGENAS 2009 http://bit.ly/29MBD4l 
  Minimal-invasiver perkutaner Aortenklappenersatz LBI-HTA Update 
2009 
http://bit.ly/29JzsQr 
  Minimal-invasiver perkutaner Aortenklappenersatz LBI-HTA Update 
2010 
http://bit.ly/29KrhVJ 
  Minimal-invasiver perkutaner Aortenklappenersatz/TAVI LBI-HTA Update 
2011 
http://bit.ly/29ESJ6f 
  Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults  HIS 2011 http://bit.ly/29LMw6O 
  Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults  HIS 2011 http://bit.ly/29Jyvb2 
  Transcatheter Aortic Valve Implantation (TAVI): a Health Technology Assessment Update KCE 2011 http://bit.ly/29ATCKD 
  The cost of innovation in treating aortic stenosis: transcatheter aortic valve implantation ASSR 2012 http://bit.ly/29AIsqi 
  Transcatheter aortic valve implantation for aortic stenosis NICE 2012 http://bit.ly/29A1pwd 
  JenaVALVE TAVI System HAS 2013 http://bit.ly/29KqKmU 
  Efficacy and safety of percutaneous and transapical aortic valve implantation in the 
treatment of severe aortic stenosis. Systematic review  
AVALIA-T 2013 http://bit.ly/29AUF15 
  Cost-effectiveness of Transcatheter Aortic Valve Implantation (TAVI) for Aortic Stenosis in 
patients who cannot undergo surgery  
NIHR 2013 http://bit.ly/29JhrlP 
  Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in 
adults at high surgical risk  
HIS 2014 http://bit.ly/29Kq40A 
  Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in 
adults who are not eligible for surgery 
HIS 2014 http://bit.ly/29ATJpt 
  Evaluatie indicatieprotocol TAVI  ZIN 2014 http://bit.ly/2a4Ijdp 
  Cost-effectiveness of percutaneous aortic valve replacement using prosthetic valve versus 
the standard surgical treatment 
OSTEBA 2014 http://bit.ly/29F4oRt 
  Effect of severe left ventricular systolic dysfunction on hospital outcome after transcatheter 
aortic valve implantation or surgical aortic valve replacement: results from a propensity-matched 
population of the Italian OBSERVANT multicenter study 
ASSR 2014 http://bit.ly/29O6s8I 
  Development of appropriateness criteria for transcatheter aortic valve implantation (TAVI) 
for severe symptomatic aortic stenosis 
AVALIA-T 2014 http://bit.ly/29AU6jy 
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Technology HTA title Institute Year Link-shortened 
Implantable cardiac 
resynchronization therapy and 
defibrillator (CRT-D/CRT-P)  
Cardiac Resynchronization Therapy (CRT) in Chronic Heart Failure SBU 2003 http://bit.ly/2bOEb2h 
 The use of cardiac resynchronization therapy (CRT) for heart failure  HIS 2005 http://bit.ly/29Jzbgv 
 The Implantable Cardioverter Defibrillator: a Health Technology Assessment KCE 2007 http://bit.ly/29N5Y3d 
 The clinical effectiveness and cost-effectiveness of cardiac resynchronization (biventricular 
pacing) for heart failure: systematic review and economic model  
NIHR 2007 http://bit.ly/29A8kzX 
 Standards for health technologies appropriateness: Cardiac resynchronization therapy AETSA 2009 http://bit.ly/29KrisN 
 Cardiac Resynchronisation Therapy. Economic evaluation  UETS 2010 http://bit.ly/29F4XKX 
 Cardiac Resynchronisation Therapy KCE 2011 http://bit.ly/29uW5oI 
 Implantable cardiac resynchronization therapy and defibrillator (CRT-D) in patient with 
heart failure 
AGENAS 2014 http://bit.ly/29Jzc48 
 Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac 
resynchronization therapy for the treatment of heart failure: systematic review and 
economic evaluation  
NIHR 2014 http://bit.ly/29Jz98x 
 Implantable cardioverter defibrillators and cardiac resynchronization therapy for 
arrhythmias and heart failure 
NICE 2014 http://bit.ly/29SP3OQ 
 Le stimulateur cardiaque de resynchronisation dans le traitement de l’insuffisance cardiaque  Swiss Medical 
Board  
2015 http://bit.ly/29AJ4fx 
Drug-eluting stents (DES) for 
Peripheral Artery Disease (PAD) 
Senkung der Restenoserate durch Einsatz beschichteter Stents bei koronarer Herzkrankheit  DIMDI 2005 http://bit.ly/29sSDi7 
 Economic Evaluation of Drug Eluting Stents for high risk indications UETS 2006 http://bit.ly/29xyXoz 
 Drug-eluting stents in Belgium: Health Technology Assessment  KCE 2007 http://bit.ly/29UaXRN 
 Drug-eluting stents for the treatment of coronary artery disease NICE 2008 http://bit.ly/29SPngJ 
 Évaluation des endoprothe ̀ses coronaires à libe ́ration de principe actif  HAS 2009 http://bit.ly/29sSlb2 
 Cost effectiveness of different types of coronary stents which are used in patients with 
acute coronary syndrome (ACS)  
UETS 2013 http://bit.ly/29xznv8 
 Economic evaluation of drug eluting stents in the treatment of ischemic heart disease (update)  UETS 2013 http://bit.ly/2a4JJ7D 
 Medikamenten-freisetzende Stents bei peripherer arterieller Verschlusskrankheit LBI-HTA 2014 http://bit.ly/29SPbOC 
 Drug-eluting stents in coronary arteries SBU 2014 http://bit.ly/29AU9w1 
 New-generation drug-eluting stents reduce stent thrombosis and myocardial infarction:  
a propensity-score-adjusted analysis from the multicenter REAL registry (REgistro Regionale 
Angioplastiche dell’Emilia-Romagna) 
ASSR 2014 http://bit.ly/29AIWwC 
 Antiko ̈rperbeschichtete, medikamentenfreisetzende Stents zur Behandlung von 
Koronargefa ̈ßstenosen  
IQWIG 2015 http://bit.ly/1SZJr0A 
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Technology HTA title Institute Year Link-shortened 
 Drug eluting balloons and stents for symptomatic peripheral arterial disease  The Regional 
Health Technology 
Assessment Centre 
(HTA-centrum)  
2015 http://bit.ly/29LNaRC 
MitraClip® Perkutane Mitralklappenintervention mittels MitraClip bei Mitralklappeninsuffizienz LBI-HTA 2010 http://bit.ly/29Ub4Nh 
 Perkutane Mitralklappenintervention mittels MitraClip bei Mitralklappeninsuffizienz.  
1. Update 2012 
LBI-HTA 2012 http://bit.ly/29AUrqy 
 MitraClip®  The HTA Center  
of the Stockholm 
County Council/ 
Gotland 
2012 http://bit.ly/29LNzU9 
 Mitraclip® – clip de réparation mitrale CEDIT 2012 http://bit.ly/29LMKLj 
 przezcewnikowa nieoperacyjna naprawa zastawki mitralnej (MitraClip) u chorych 
wysokiego ryzyka  
AOTMit 2013 http://bit.ly/29MHcPX 
 Using MitraClip® to repair mitral valve regurgitation  OSTEBA 2014 http://bit.ly/29A2ynp 
 Evaluation d’un clip de re ́paration mitrale bord à bord et de son acte d’implantation  HAS 2015 http://bit.ly/1Q1h5CN 
 Perkutane Mitralklappenreparatur bei chronischer Mitralklappeninsuffizienz (MitraClip®, 
Carillon®, NeoChord DS1000). Deutsche Kurzfassung zum gleichnamigen EUnetHTA Bericht 
LBI-HTA 2015 http://bit.ly/29vHglg 
 What is the effectiveness, safety and cost-effectiveness of the MitraClip® transcatheter mitral 
valve repair system in patients with moderate to severe or servere mitral regurgitation who 
are at high surgical risk or are non-surgical candidates? 
HIS 2016 http://bit.ly/29A2S5J 
Intensity-modulated radiation 
therapy (IMRT) 
Clinical and cost-effectiveness of new and emerging technologies for early localised prostate 
cancer: a systematic review  
NIHR 2003 http://bit.ly/29xzx5K 
 Radioterapia de intensidad modulada  AVALIA-T 2005 http://bit.ly/29MCCRL 
 Radiothe ́rapie extracra ̂nienne en conditions ste ́re ́otaxiques  HAS 2006 http://bit.ly/29ESU19 
 Intensity-modulated radiotherapy (IMRT) KCE 2007 http://bit.ly/29Bcjwk 
 Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review 
and economic evaluation  
NIHR 2010 http://bit.ly/29O79i9 
 A study on efficacy, effectivity and efficiency of Intensity Modulated Radiotherapy (IMRT). 
Utility for treatment of breast and central nervous system neoplasms and sarcomas of bones 
and soft tissue.  
AETSA 2010 http://bit.ly/29AJjau 
 Innovative radiation treatment in cancer: IGRT/IMRT  ASSR 2010 http://bit.ly/29LNf81 
 Innovative radiotherapy techniques: a mulitcentre time-driven activity-based costing study KCE 2013 http://bit.ly/29DQrnB 
 An evaluation of intensity-modulated radiotherapy (IMRT) OSTEBA 2014 http://bit.ly/29MCzFO 
 New IMRT techniques for moving targets. An analysis of their safety and ef cacy.  OSTEBA 2014 http://bit.ly/29DPTy7 
 Radiothe ́rapie conformationnelle avec modulation d’intensite ́ dans le cancer du canal anal HAS 2015 http://bit.ly/29AV83e 
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Technology HTA title Institute Year Link-shortened 
High intensity focused 
ultrasound (HIFU) 
Clinical and cost-effectiveness of new and emerging technologies for early localised prostate 
cancer  
NIHR 2003 http://bit.ly/29xzx5K 
 High-intensity focused ultrasound for prostate cancer  NICE 2005 http://bit.ly/29JB5O7 
 Efficacy, safety of high intensity focused ultrasound (HIFU-ExAblate)  UETS 2007 http://bit.ly/29JARGK 
 Nichtmedikamentoese lokale Verfahren zur Behandlung des benignen Prostatasyndroms IQWIG 2009 http://bit.ly/29F7nJw 
 Destruction par ultrasons focalise ́s de haute intensite ́ par voie rectale d’un ade ́nocarcinome 
localise ́ de la prostate  
HAS 2010 http://bit.ly/29MCTnL 
 Hochintensiver Fokussierter Ultraschall (HIFU) zur Behandlung des Prostatakarzinoms LBI-HTA 2010 http://bit.ly/29O7u4C 
 Ultrasonido focalizado de alta intensidad (HIFU) extracorporeo en tumores solidos 
[Extracorporeal High-Intensity Focused Ultrasound (HIFU) in solid tumours] 
CAHIAQ (AQuAs) 2010  
 Nichtmedikamentoese lokale Verfahren zur Behandlung des benignen Prostatasyndroms G-BA 2010 http://bit.ly/29xAgnj 
 HTA Report: Trattamento del carcinoma della prostata mediante termoablazione con HIFU AGENAS 2011 http://bit.ly/2a4KGNr 
 New treatments in organ-confined cancer vs. prostatectomy. Systematic review. Ablation 
with cryotherapy, HIFU and laser therapy.  
AETSA 2013 http://bit.ly/29Ks35b 
 High-intensity focused ultrasound (HIFU) bij prostaatcarcinoom  ZIN 2013 http://bit.ly/29xA6fD 
 Leczenie raka stercza skupiona ̨ wiązka ̨ ultradźwie ̨kową (HIFU)  AOTMit 2014 http://bit.ly/29BcuI7 
Lumbar total disc replacement  Remplacement du disque interverte ́bral lombaire par prothe ̀se  HAS 2007 http://bit.ly/29BPxa8 
 Prosthetic intervertebral disc replacement in the lumbar spine NICE  2009 http://bit.ly/29JBoIL 
 Bandscheibenprothesen LBI-HTA 2010 http://bit.ly/29MdZbv 
 So ̈kning i databaser fo ̈r vetenskaplig evidens: Diskproteskirurgi i la ̈ndryggen  Metodrådet i 
Sydöstra 
Sjukvårdsregionen 
2013 http://bit.ly/29MDBBL 
 Lumbar total disc replacement effectiveness and safety in chronic low back pain  AETSA 2014 http://bit.ly/29LO40w 
 Cervical and Lumbar total disc replacements KCE 2015 http://bit.ly/29tGA4l 
 Operative versus konservative Behandlung von Diskushernien Swiss Medical 
Board  
2015 http://bit.ly/29LO0xH 
 [Protesizzazione del disco intervertebrale cervicale e lombare] – HTA report adaptation di 
„Cervical and lumbar total disc replacements“ Health Technology Assessment (HTA) Brussels: 
Belgian Health Care Knowledge Centre (KCE). 2015. KCE Reports 254. D/2015/10.273/94. 
AGENAS 2016 nichtauffindbar 
Intraoperative radiation 
therapy (IORT) 
Intraoperative Radiotherapie bei fruehem Brustkrebs LBI-HTA 2009 http://bit.ly/29BPZFn 
 Innovative radiotherapy techniques: a multicenter time-driven activity-based costing study KCE 2013 http://bit.ly/29DQrnB 
 Intraoperative radiation therapy in the treatment of breast cancer  AVALIA-T 2013 http://bit.ly/1myxMpY 
 Intraoperative radiation therapy in the treatment of colorectal cancer AVALIA-T 2014 http://bit.ly/29DQQ9z 
 Evaluation de la radiothe ́rapie perope ́ratoire dans le cancer du sein  HAS 2015 http://bit.ly/29KMInU 
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Technology HTA title Institute Year Link-shortened 
Sacral nerve stimulation (SNS) 
for the treatment of fecal 
incontinence 
Sacral nerv stimulation for faecal incontince NICE  2004 http://bit.ly/29MEiuy 
 Sakralnervstimulering (SNS) vid fekal inkontinens  Västra Götalands-
regionen, 
Sahlgrenska Uni-
versitetssjukhuset 
2009 http://bit.ly/29xAH0S 
 Sakralnervstimulation bei faekaler Inkontinenz LBI-HTA 2011 http://bit.ly/2a8Hnc4 
 INTERSTIM (I ET II)  HAS 2013 http://bit.ly/29yUSM7 
 Sacral nerve stimulation for the treatment of fecal in- continence: an effectiveness review 
and cost-effective- ness analysis  
CAHIAQ (AQuAs) 2014 http://bit.ly/29KsY5s 
 Management of incontinence:sacral nerve stimulation vs. electrical stimulation VASPVT 2014  
 Standpunt Sacrale neurostimulatie bij kinderen en volwassenen met therapieresistente 
functionele obstipatie 
ZIN 2014 http://bit.ly/29SQGvV 
 Secca System for faecal incontinence  NICE 2016 http://bit.ly/29uJD7L 
Robot-assisted surgery system  Robot-assisted surgery using da Vinci® robot telemanipulation in prostatectomy  AETSA 2007 http://bit.ly/29uJAZF 
 Robotic surgery by means of the da Vinci® robotic telemanipulation system in 
cardiovascular surgery  
AETSA 2007 http://bit.ly/29ETQCQ 
 Robotic surgery by means of the da Vinci® robotic telemanipulation system in general and 
digestive surgery  
AETSA 2007 http://bit.ly/29yULQI 
 Robotic surgery using the da Vinci® robotic telemanipulation system in hysterectomy  AETSA 2007 http://bit.ly/29Me1Qk 
 La chirurgia robotica: il robot da vinci  ASSR 2008 http://bit.ly/29F7vc4 
 Robot-assisted surgery: health technology assessment  KCE 2009 http://bit.ly/29GiMsC 
 Revision sistematica de las evaluaciones economicas de la cirurgia mediante equipo 
quirurgico da Vinci  
UETS 2011 http://bit.ly/29uJrWb 
 Systematic review and economic modelling of the relative benefit and cost-effectiveness of 
laparoscopic surgery and robotic surgery for removal of the prostate in men with localized 
prostate cancer  
NIHR 2012 http://bit.ly/2a64TlG 
 Robotique chirurgicale en pe ́diatrie  CEDIT 2014 http://bit.ly/29uJf9k 
 Roboterassistierte Chirurgie: Eine systematische Uebersichtsarbeit zu Wirksamkeit und 
Sicherheit bei ausgewaehlten Indikationen und anfallenden Kosten  
LBI-HTA 2015 http://bit.ly/29Bd9cj 
 Évaluation des dimensions clinique et organisationnelle de la chirurgie robot-assiste ́e dans le 
cadre d’une prostatectomie totale  
HAS 2015 http://bit.ly/29O96eo 
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Figure 8-1: Evidence pyramid for implantable cardiac resynchronization therapy (CRT) 
(green = used evidence, blue (and white) = not used evidence) 
 
Figure 8-2: Evidence pyramid for MitraClip® 
(green = used evidence, blue (and white) = not used evidence) 
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Quasi-experimental studies – a 
RCTs – b, d 
System. Reviews – c 
MAs 
Background information/Expert Opinion 
Animal Research/Laboratory Studies 
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Figure 8-3: Evidence pyramid for Intensity-modulated radiation therapy (IMRT) 
(green = used evidence, blue (and white) = not used evidence) 
 
Figure 8-4: Evidence pyramid for high intensity focused ultrasound (HIFU) 
(green = used evidence, blue (and white) = not used evidence) 
Case series/Case reports – a 
Case control studies 
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Animal Research/Laboratory Studies 
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Figure 8-5: Evidence pyramid for lumbar total disc replacement 
(green = used evidence, blue (and white) = not used evidence) 
 
Figure 8-6: Evidence pyramid for intraoperative radiotherapy (IORT) 
(green = used evidence, blue (and white) = not used evidence) 
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Figure 8-7: Evidence pyramid for sacral nerve stimulation (SNS) 
(green = used evidence, blue (and white) = not used evidence) 
 
Figure 8-8: Evidence pyramid for robot-assisted surgery system 
(green = used evidence, blue (and white) = not used evidence) 
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Figure 8-9: Evidence pyramid for drug-eluting stents (DES) 
(green = used evidence, blue (and white) = not used evidence) 
 
Figure 8-10: Evidence pyramid for Transcatheter Aortic Valve Implantation (TAVI) 
(green = used evidence, blue (and white) = not used evidence) 
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